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Diphthamide is a post-translationally modified histidine residue found in eukaryotic 
and archael elongation factor 2 (EF2). Diphtheria toxin (DT) and the Pseudomonas 
exotoxin A (ETA) catalyze the ADP-ribosylation reaction on the diphthamide residue 
of EF-2 and therefore inactivate EF-2 and stop ribosomal protein synthesis. Proposed 
biosynthetic pathway of diphthamide has three steps. In eukaryotes, there are five 
participating genes, namely DPH1 – DPH5, have been identified. The first step 
requires four proteins, Dph1-4, while the second step requires a single protein, Dph5. 
In contrast, the enzyme required for the last amidation step has remained unknown 
even three decades after the structure of diphthamide was revealed.  
I started my work on the first step modification. Yeast Dph1 and Dph2 were expressed 
and purified and were shown to be active in S-adenosyl methionine (SAM) cleavage, 
but not in the 3-amino-3-carboxypropyl (ACP) group transfer. Yeast ORF YBR246W 
was then studied, which was reported to be required for diphthamide biosynthesis. Our 
results showed that diphthine accumulates in the YBR246W deletion strain. Therefore 
YBR246W is required for the amidation step of diphthamide biosynthesis. Following 
this functional study, I discovered the diphthamide synthetase, YLR143W using yeast 
co-fitness analysis. We have been able to show that YLR143W catalyzes the diphthine 
amidation reaction in vitro. The nitrogen source of this reaction is ammonium and 
 AMP is generated. The human orthologue ATPBD4 is also a diphthamide synthetase. 
Further study revealed that YBR246W's activity is required prior to the activity of 
YLR143W. So there should be a minimum of four steps in diphthamide biosynthetic 
pathway.  
The final part of my thesis describes our work on a human sirtuin SIRT5. Sirtuins are 
a family of NAD-dependent deacetylases. Our crystallography and biochemical 
studies showed that Sirt5 prefers to catalyze demalonylation and desuccinylation 
instead of deacetylation. A number of lysine succinylation sites were identified on 
bovine glutamate dehydrogenase (GDH) and other proteins. Sirt5 was shown to 
regulate succinylation and activity of carbamoyl-phosphate synthase 1 (CPS1). 
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CHAPTER 1 
AN OVERVIEW OF DIPHTHAMIDE BIOSYNTHESIS 
Introduction 
Diphthamide is a post-translationally modified histidine residue found in eukaryotic and archael 
elongation factor 2 (EF2). It is named after the fact that it is the target of diphtheria toxin 
produced by  Corynebacterium diphtheriae. Diphtheria toxin (DT) and the Pseudomonas 
exotoxin A (ETA) catalyzes the ADP-ribosylation reaction on the diphthamide residue of EF-2 
using nicotinamide adenine dinucleotide (NAD) as the ADP-ribosyl donor(1). EF-2 catalyzes the 
translocation step and the ADP-ribosylation of EF-2 inactivates it, stopping protein synthesis and 
leads to cell death(2, 3). 
Structure determination of diphthamide and the identification of DPH genes 
The study of diphthamide started with the elucidation the DT modification site. It was first 
discovered that the target residue of diphtheria toxin is not an ordinary amino acid residue(4). It 
was further revealed that diphthamide exists only on EF-2 and there is one diphthamide residue 
per EF-2 protein(5). The modification sites were determined in both rat and yeast. The 
surrounding residues were found to be highly conserved(5). The structure of ADP-ribosyl 
diphthamide was determined using NMR and later confirmed by fast atom bombardment mass 
spectrometry(6, 7). The structure of diphthamide was proposed as 2-[3-carboxyamido-3-
(trimethylammonio)propyl]histidine (Figure 1). The structure determination has also been 
confirmed by X-ray crystallography(3, 8). However, there is a noteworthy discrepancy on the 
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stereochemistry of diphthamide. Crystal structure of the eEF-2 showed R configuration on the 
third carbon of diphthamide side chain(3, 8). 
 
Figure 1.1 The structure of diphthamide and ADP-ribosylation reaction. 
The structure determination allowed the proposal of the diphthamide biosynthetic pathway. By 
using biosynthetic labeling technique, it became clear that the backbone and the three methyl 
groups of diphthamide come from S-adenosylmethionine (SAM)(9). The study of diphtheria toxin 
resistant mutants of CHO-K1 Chinese hamster ovary cells revealed that there are a minimum of 
three steps(10). A genetic screening method for diphthamide deficient strains was developed 
based on the toxin sensitivity of the yeast spheroplasts(11). Five complementation groups were 
found and they were designated dph1, dph2, dph3, dph4 and dph5. Heterozygous diploid 
produced by mating wild-type and the mutants showed that the resistant phenotype is recessive to 
the sensitive phenotype(11). It became clear later that Dph1-4 are responsible for the first step(12) 
(Figure 1.2), which is the transfer of the 3-amino-3-carboxypropyl (ACP) group. Dph5 is a 
methyltransferase that produces diphthine intermediate(12). Diphthine can be ADP-ribosylated, 
but the reaction rate was only 3% of the diphthamide ADP-ribosylation reaction(12). It was also 
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suggested that there is a diphthine amidation step following the Dph5 trimethylation. But the 
amidation enzyme remained unknown for almost three decades. It was speculated that the missing 
of diphthamide synthetase in the genetic screening was because diphthine can already be ADP-
ribosylated by the toxin. Therefore, the original screening condition did not allow the emerge of 
the gene(s) responsible for the amidation reaction.  
 
Figure 1.2 The proposed biosynthetic pathway of diphthamide. The origin of each functional 
group is colored. 
Activity and function of the DPH genes 
The first step of diphthamide biosynthesis is the transfer of the ACP group from SAM to the C2 
position of the imidazole ring of the histidine residue being modified in EF-2. This reaction has 
been reconstituted in vitro and studied in great detail using the enzyme from an archaeal species 
Pyrococcus horikoshii(13). Unlike yeast, Pyrococcus horikoshii has only one gene to catalyze 
this step. The Pyrococcus horikoshii Dph2 (PhDph2) is homologous to eukaryotic Dph1 and 
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Dph2. Crystal structure of PhDhp2 homodimer was solved. PhDph2 forms a homodimer and 
contains one [4Fe-4S] cluster per monomer. Each PhDph2 monomer consists of three domains 
with similar folding pattern. The basic domain folding pattern is a four-stranded parallel -sheet 
with three flanking -helices(13). PhDph2 lacks the CX3CX2C motif which is present in most 
radical SAM enzymes(14), but contains three cysteine residues Cys59, Cys163 and Cys287 that 
are spatially closed and coordinate the [4Fe-4S] cluster. PhDph2 has been found to be active only 
under anerobic condition. PhDph2 does not generate 5'-deoxyadenosyl radical as most radical 
SAM enzymes do. Instead, PhDph2 cleaves the C,Met–S bond of SAM to form 5'-deoxy-5'-
methylthioadenosine (MTA) and ACP radical. The ACP radical attacks the histidine residue to 
give the final product.  
In Saccharomyces cerevisiae the first step is considerably more complicated than in Pyrococcus 
horikoshii. There are 4 genes known to be required for this step, DPH1-4. Dph1 and Dph2 are 
homologous to each other and presumably form a heterodimer. Dph1/Dph2 dimer may work in a 
different way than PhDph2. It has been shown that PhDph2 forms a homodimer but only one 
active monomer is required for the activity(15). In yeast, both Dph1 and Dph2 are required. The 
PhDph2 has three cysteine residues coordinating the [4Fe-4S] cluster. These three cysteine 
residues are well conserved in Dph1, while the Dph2 has only the first and the third cysteine 
residues in place. The functional implication of this asymmetry awaits further study. It is not clear 
whether Dph1/Dph2 dimer is sufficient for the ACP transfer in vitro. It is also not clear whether 
other protein factors are required for this step.  
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Dph3 from Saccharomyces cerevisiae is as small as 82 amino acids. However, there are two 
domains, a N-terminal cystathionine -synthase (CBS) domain and a C-terminal Zn ribbon 
domain(16). The solution structure of Dph3 structure was reported, which comprises a 310 helix, 
two turns, two  helices and two  sheets(17). The C-terminal Zn ribbon domain has 4 conserved 
cysteine residues arranged in Cys-X-Cys-X19-Cys-X2-Cys motif. The Zn ribbon domain was 
found to bind both zinc and iron. Dph3 can be reduced by E. coli rubredoxin reductase NorW, 
suggesting its role as a rubredoxin-like electron carrier(16).  
Dph3 has been studied for functions other than diphthamide biosynthesis. dph3 grows slower 
compared to other DPH gene deletion strains, implying that it has multiple functions(18). So far, 
people have shown that several DPH3 binding partners, including Elongator complex(19, 20), 
DelGEF (21) and yeast homologues of endophilin and amphiphysin(22). The physical 
interactions of Dph3 imply a variety of physiological functions, spanning from transcription 
regulation to endocytosis and secretion. The study of biochemical role of Dph3 in diphthamide 
biosynthesis is likely to shed light on its other cellular functions and vice versa. 
Yeast Dph4 has an N-terminal J domain which is commonly found in co-chaperone proteins. The 
C-terminal of Dph4 is the CSL zinc finger(23). The J domain is required for the activity of Dph4. 
However, a chimeric version of Dph4 with the J domain from Ydj1 is also active(23). The 
cysteine residue in the CSL tripeptide is also important for its activity. The CSL zinc finger in 
Dph4 is shown to bind Fe more tightly than Zn. Iron binding induces the oligomerization of Dph4. 
The iron containing Dph4 is redox-active(24). 
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Dph5 is a methyltransferase which catalyzes the trimethylation of the amino group(25). The 
product of this step was named diphthine. Like most other methyltransferases, Dph5 uses SAM as 
the methyl group donor. eEF-2 from dph5 has a very weak activity as the substrate for ADP-
ribosylation, about 106 times weaker than the eEF-2 from the wild-type strain(26). The diphthine-
containing eEF-2 which was obtained by in vitro methylation using purified Dph5 is a much 
better substrate for ADP-ribosylation, about 30 times weaker than wild-type eEF-2(12). 
Diphthine amidation was reconstituted in vitro using yeast cell lysate. It was revealed that this 
reaction is ATP-dependent. The identity of the nitrogen source was elusive.  
Pyrococcus horikoshii Dph5 (PhDph5) was also studied in diphthine formation. PhDph5 was able 
to catalyze the trimethylation reaction in a highly processive manner. Interestingly, it was found 
that diphthine on PhEF-2 is not stable. It tends to lose the trimethylamino group in a reaction that 
is similar to Hofmann elimination(27). This reaction does not happen readily on yeast diphthine. 
The exact mechanism and implication of this reaction is unknown. However, this may help to 
explain the weak activity of archeal EF-2 as substrates in ADP-ribosylation reactions(28).  
The biological function of diphthamide 
The biological function of diphthamide has been elusive. Diphthamide modification makes cell 
susceptible to bacterial toxins, yet it is highly conserved among archaea and eukaryotes. The 
formation of diphthamide involves multiple proteins and enzymatic steps. It is hard to believe that 
such a system exists only to be exploited by bacterial toxins. These facts suggest a fundamental 
role of diphthamide. However, in yeast none of the DPH genes is essential. Therefore the true 
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function of diphthamide is mysterious. It has long been speculated that diphthamide is the target 
of endogenous ADP-ribosyltransferases. Bacterial toxin induced ADP-ribosylation shuts down 
ribosomal protein synthesis and kills host cells. It has been reported that diphthamide can also be 
ADP-ribosylated by endogenous ADP-ribosyltransferase and this is a regulatory mechanism for 
cellular protein synthesis(29). The endogenous ADP-ribosyltransferase activity was found from 
both polyoma virus-transformed baby hamster kidney (pyBHK) cells (29) and beef liver(30). 
However, later studies showed that the eEF-2 ADP-ribosylation activity from pyBHK cells was 
independent of diphthamide modification(31, 32). It has also been reported that interleukin-1 
may act as an activator of the endogenous ADP-ribosylation(33). To the best knowledge of the 
authors, there has not been any endogenous diphthamide ADP-ribosyltransferase cloned and 
characterized. 
Despite the fact that yeast strains lacking DPH genes grow normally, DPH genes have much more 
important functions in mammals. DPH1 gene has been found to be frequently deleted in ovarian 
and breast cancer, hence the alias OVCA1 (ovarian cancer gene 1)(34-36). Overexpression of 
OVCA1 suppresses the colony formation of ovarian cancer cells, presumably by cell cycle arrest 
at G1 phase(37). It was further demonstrated that OVCA1 overexpression in ovarian cancer cells 
A2780 leads to down-regulation of cyclin D1, and up-regulation of p16(38). OVCA1 
homozygous mutant mice die at birth due to developmental delay and multiple organ defects. 
OVCA1 heterozygous mice develop cancer spontaneously(39). Similar to DPH1, DPH3 
homozygous deletion leads to embryonic death(40) and DPH4 homozygous mutants were 
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retarded in growth and development(41). These developmental defects has been attributed to the 
deficiency of diphthamide(42).  
Diphthamide has been found to be important in maintaining translational fidelity. The lack of 
diphthamide results in elevated -1 frameshift in protein synthesis(43). Diphthamide resides in the 
tip of domain IV of eEF2 which is in close proximity with the tRNA in the P-site(44). The 
positive charge brought by diphthamide modification helps eEF-2 to maintain conformational 
integrity(42). These discoveries provide a molecular insight of diphthamide function in 
development and tumorigenesis. 
It is not clear whether diphthamide modification is a regulated process or not. However, 
evidences were provided that 5'-deoxy-methylthioadenosine inhibits diphthamide 
biosynthesis(45). This is probably because of the inhibition on the first step.  
Dissertation statement 
My graduate work touches on several steps of diphthamide biosynthesis. In Chapter 2, I describe 
my work on the first step modification. We have expressed and purified yeast Dph1 and Dph2 
and showed that the proteins are active in SAM cleavage, but not in ACP group transfer. Chapter 
3 described the functional study of yeast ORF YBR246W, which was reported to be required for 
diphthamide biosynthesis. Our results showed that diphthine accumulates in the YBR246W 
deletion strain. Therefore YBR246W is required for the amidation step of diphthamide 
biosynthesis. In Chapter4, I described the discovery of diphthamide synthetase, YLR143W,  
 9 
 
using yeast co-fitness analysis. We have been able to show that YLR143W catalyzes the 
diphthine amidation reaction in vitro. The nitrogen source of this reaction is ammonium and AMP 
is generated. The human orthologue ATPBD4 is also a diphthamide synthetase. In Charpter 5, I 
further discussed the possible biochemical role of YBR246W. We found that there are actually 
two diphthine-containing eEF-2 species, one can be amidated and the other one cannot. So there 
should be a minimum of four steps in diphthamide biosynthetic pathway. YBR246W works after 
Dph5 and before YLR143W. Chapter 6 describes our work on a human sirtuin SIRT5. Sirtuins 
are a family of NAD-dependent deacetylases. Our crystallography and biochemical studies 
showed that Sirt5 prefers to catalyze demalonylation and desuccinylation instead of deacetylation. 
a number of lysine succinylation sites were identified on bovine glutamate dehydrogenase (GDH) 
and other proteins. Sirt5 was shown to regulate succinylation and activity of carbamoyl-
phosphate synthase 1 (CPS1).
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CHAPTER 2 
YBR246W IS REQUIRED FOR THE THIRD STEP OF DIPHTHAMIDE 
BIOSYNTHESIS 
Abstract 
Diphthamide, the target of diphtheria toxin, is a post-translationally modified histidine residue 
that is found in archaeal and eukaryotic translation elongation factor 2. The biosynthesis and 
function of this modification has attracted the interest of many biochemists for decades. The 
biosynthesis has been known to proceed in three steps. Proteins required for the first and second 
steps have been identified, however, the protein(s) required for the last step remained elusive. 
Here we demonstrate that the YBR246W gene in yeast is required for the last step of diphthamide 
biosynthesis, as the deletion of YBR246W leads to the accumulation of diphthine, which is the 
enzymatic product of the second step of the biosynthesis. This discovery will provide important 
information to finally complete the full biosynthesis pathway of diphthamide.   
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Introduction 
Diphthamide is a post-translationally modified histidine found on archaeal and eukaryotic 
translational elongation factor 2 (eEF-2)(1-4). Diphthamide is the target of the diphtheria toxin 
(DT), which is an exotoxin produced by Corynebacterium diphtheria(5).  The toxin ADP-
ribosylates diphthamide and therefore inactivates eEF-2 to stop ribosomal protein synthesis. 
While being highly conserved from archaea to eukaryotes, the biological function of diphthamide 
remains poorly understood. The diphthamide modification has been reported to regulate 
translational fidelity in protein synthesis and the lack of diphthamide results in increased -1 
frameshift mutation(6). However, no significant phenotype other than the toxin sensitivity has 
been linked to the lack of diphthamide modification in yeast.  
The biosynthetic pathway of diphthamide has been elucidated in yeast and mammalian cells by 
biochemical and genetic studies(7-15). There are three steps in the diphthamide biosynthesis and 
five participating genes, namely DPH1 – DPH5, have been identified (Figure 2.1). The first step 
requires four proteins, Dph1-4, while the second step requires a single protein, Dph5.  In 
contrast, the enzyme required for the last amidation step has remained unknown even three 
decades after the structure of diphthamide was revealed.  
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Figure 2.1 Biosynthesis pathway of diphthamide. 
Recently, we have reconstituted the first and second step of diphthamide biosynthesis in vitro 
using proteins from a thermophilic archaea, P. horikoshii(16-18). Archaeal diphthamide 
biosynthesis differs from the eukaryotic system in that among the four proteins (Dph1-Dph4) 
required for the first step, only one (Dph2) is present in archaea. P. horikoshii Dph2 (PhDph2) 
forms a homodimer in vitro, and uses a [4Fe-4S] cluster to generate a 3-amino-3-carboxypropyl 
radical to catalyze the first step of diphthamide biosynthesis(16). Based on what was learned from 
PhDph2 and that eukaryotic Dph1 and Dph2 are homologous and exist in a complex, we 
hypothesized that eukaryotic Dph1 and Dph2 forms a heterodimer and is functionally equivalent 
to PhDph2 homodimer(16). Dph3 and Dph4 most likely are required for the assembly of the 
[4Fe-4S] cluster or maintaining the [4Fe-4S] cluster in the correct redox state. Interestingly, one 
more protein, the product of yeast open reading frame (ORF) YBR246W, recently was reported 
 20 
 
to be required for the first step of diphthamide biosynthesis(19). Because of our long standing 
interest in the enzymology of diphthamide biosynthesis, this report triggered us to ask two 
questions. Is YBR246W really required for the first step? If so, what is the molecular role of 
YBR246W in the first step? Thus, we set out to validate the reported functional assignment of 
YBR246W.  Our results show that YBR246 is actually required for the third step of diphthamide 
biosynthesis. This corrected assignment for the function of YBR246W provides important 
information that will lead to the complete identification of the missing enzyme for the last step of 
diphthamide biosynthesis. 
 
Results and discussion 
YBR246W is required for diphthamide biosynthesis 
To confirm the involvement of YBR246W in diphthamide biosynthesis, we first performed an in 
vitro ADP-ribosylation reaction. His6-tagged eEF-2 was overexpressed and purified from wild-
type (WT) and DPH gene deletion strains. A rhodamine-labeled NAD compound (Rh-NAD) was 
used in DT-catalyzed ADP-ribosylation reaction to visualize the product(20). Without DT, eEF-2 
was not labeled (Figure 2). When 0.1 μM DT was used, the eEF-2 from WT yeast strain was 
clearly labeled. The eEF-2 from Δdph2 or Δybr246w was not labeled (Figure 1). This result was 
consistent with the previous report that YBR246W is required for diphthamide biosynthesis(19). 
Without YBR246W, diphthamide modification is impaired and cannot be ADP-ribosylated 
efficiently.  
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Figure 2.2 In vitro ADP-ribosylation using Rh-NAD. The upper panel was Coomassie blue-
stained SDS-PAGE gel showing the eEF-2 proteins and the lower panel shows the corresponding 
fluorescence labeling. The source strains from which the eEF-2 proteins were purified were 
labeled above. No DT was added in lane 1-3 and 100 nM DT was added to lane 4-6. Reactions 
were carried out at 30°C for 20 min. 
In vivo DT resistance assay revealed a different function of YBR246W  
We then tested the requirement of YBR246W in diphthamide biosynthesis using an in vivo DT 
resistance assay. This assay was similar to the one used to identify DPH1-DPH5 that are required 
for diphthamide biosynthesis(8, 11). WT, Δdph1-Δdph5, and Δybr246w strains were transformed 
with the pLMY101 plasmid(11), which contains the catalytic domain of the DT under the control 
of GAL1 promoter. When grown in glucose (Glc) medium, all strains were viable since DT 
expression was suppressed (Figure 2.3). The Δdph3 strain showed minor growth defect due to the 
participation of DPH3 in other biological processes(14, 21). When 2% galactose (Gal) was used 
as the carbon source, the wild-type strain was killed due to the expression of the toxin, which 
ADP-ribosylates diphthamide on eEF-2. In contrast, DPH1-5 deletion strains were viable because 
they do not synthesize diphthamide. However, the Δybr246w strain failed to grow on medium 
with 2% Gal (Figure 2.4). The results showed that unlike other DPH gene deletions, the 
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YBR246W deletion does not confer DT resistance. 
 
Figure 2.3 Growth assay of DPH gene deletion strains transformed with pLMY101. The strains 
were grown on 2% Glc medium.   
 
Figure 2.4 DT sensitivity assays of WT and deletion strains. The strains were transformed with 
pLMY101, which encodes the catalytic fragment of DT, and were grown on 2% Gal medium.   
The DT sensitivity of Δybr246w was further examined by varying the Gal concentration in the 
medium to tune the expression level of DT. Raffinose (Raf) was used in combination with Gal to 
sustain the cell growth. Unlike Glc, which inhibits the GAL1 promoter transcription, Raf is a 
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neutral carbon source that does not promote nor inhibit GAL1-dependent expression. On plates 
with 2% Glc or 2% Raf, WT, Δdph2, and Δybr246w strains were all viable. When 0.001% Gal 
was added, WT strain showed severe growth defect and Δybr246w grew normally. When 0.01% 
Gal was added, the WT was completely killed and Δybr246w exhibited a significantly lowered 
viability. Neither the WT nor the Δybr246w strain was able to grow when 0.1% Gal was present 
in the medium (Figure 2.5). In contrast, the Δdph2 strain was able to grow even in the presence of 
2% Gal. This result shows that Δybr246w was only slightly more resistant to DT than WT. 
 
Figure 2.5 DT sensitivity assays of WT and deletion strains.  (A) The strains were transformed 
with pLMY101, which encodes the catalytic fragment of DT, and were grown on 2% Gal 
medium.  (B). WT, Δdph2 and Δybr246w were grown on 2% Raf plus varying concentrations of 
Gal.  The growth on 2% Glc is shown as a control. 
eEF-2 from ybr246w shows lower ability to be ADP-ribosylated 
The ADP-ribosylation results in vitro and the DT sensitivity results in vivo are seemingly in 
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conflict with each other. In other words, how can DT kill the Δybr246w yeast cells if the eEF-2 
cannot be ADP-ribosylated? Two possibilities were considered. First, YBR246W is required for 
the first step and without YBR246W only a small fraction of eEF-2 is fully modified while the 
majority remains totally unmodified. The small fraction of diphthamide modification is enough to 
confer DT sensitivity. Second, the majority of eEF-2 is actually modified but to a form that is 
different from diphthamide. To test the two possibilities, the in vitro eEF-2 labeling experiment 
was repeated with a higher concentration of the toxin. If only a small fraction of eEF-2 is fully 
modified to diphthamide and can be ADP-ribosylated, then higher toxin concentrations would 
yield the same extent of labeling. However, the experimental result showed the opposite. The 
eEF-2 from the WT strain was labeled to similar levels at both low and high toxin concentrations. 
The eEF-2 from the Δybr246w was barely labeled when 0.1 μM DT was used, but was labeled 
clearly when 10 μM of DT was used (Figure 2.6). In contrast, the eEF-2 from Δdph2 and Δdph5 
was not labeled even when high DT concentration was used (Figure 2.6 and 2.7). These results 
indicate that the eEF-2 from Δybr246w can be ADP-ribosylated by DT, but less efficiently. 
Similar results were obtained by labeling the endogenous eEF-2 (Figure 2.8). The difference in 
the ability to be ADP-ribosylated supports that eEF-2 from Δybr246w is different from the 
unmodified histidine (I in Figure 2.1), the intermediates (II in Figure 2.1) in the biosynthesis, or 
the fully modified diphthamide (IV in Figure 2.1). Thus the most logic possibility is that the eEF-
2 from Δybr246w contains another intermediate such as diphthine. 
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Figure 2.6  In vitro ADP-ribosylation assay with high concentration of DT. The upper panel 
shows a Coomassie blue-stained gel with the eEF-2 proteins and the lower panel shows the 
corresponding fluorescence labeling. The source strains from which the eEF-2 proteins were 
purified are labeled above. Reactions shown in lane 1-3 contained 0.1 μM of DT whereas those 
shown in lane 4-6 contained 10 μM of DT. Reactions were carried out at 30°C for 60 min. 
 
Figure 2.7  ADP-ribosylatability of eEF-2 from Δdph5. The upper panel was the Coomassie 
blue-stained gel showing the eEF-2 protein amount and the lower panel showed the 
corresponding fluorescence labeling. The source strains from which the eEF-2 were purified were 
shown above. Reactions shown in lane 1 and 2 contained 0.1 μM DT and reactions shown in 
lanes 3 and 4 contained 10 μM DT. Reactions were carried out at 30°C for 60 min. 
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Figure 2.8  ADP-ribosylation assay using endogenous eEF-2. The yeast total protein extraction 
was performed as described in the Method. The upper panel shows a Coomassie blue-stained gel 
with the lysate proteins and the lower panel shows the corresponding fluorescence labeling. The 
source strains from which the lysates were obtained are labeled above. Reactions shown in lane 1-
4 contained 0.1 μM of DT and those shown in lane 5-8 contained 10 μM of DT. The protein 
molecular weight marker positions are indicated on the left side. Reactions were carried out at 
30°C for 60 min.   
LC MS/MS confirmed diphthine on eEF-2 from ybr246w 
To confirm the presence of diphthine in the eEF-2 from Δybr246w, mass spectrometry (MS) 
studies were performed on eEF-2 purified from WT, Δdph2 and Δybr246w yeast strains. The 
peptide (686-VNILDVTLHADAIHR-700) containing the unmodified histidine was found in all 
three eEF-2 samples (Figure 2.9 and 2.10). The diphthamide-containing peptide was only found 
in the eEF-2 from WT strain, and the diphthine-containing peptide was found only in the eEF-2 
from Δybr246w (Figure 2.11). The identities of diphthamide and diphthine modifications on the 
peptides were supported by the MS/MS spectra (Figure 2.12). When singly charged, the peptide 
containing diphthamide is 0.984 Dalton smaller than the peptide containing diphthine. Both 
diphthamide and diphthine undergo a neutral loss of trimethylamino group during MS/MS, which 
was reported earlier(22). Because diphthine was present in Δybr246w yeast cells, we concluded 
that YBR246W is not required for the first step of diphthamide biosynthesis. The accumulation of 
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diphthine in Δybr246w but not in WT suggests that YBR246W is required for the last amidation 
step of diphthamide biosynthesis. 
 
Figure 2.9  Extracted ion chromatograms of the unmodified peptides from WT, Δdph2 and 
Δybr246w. The peaks corresponding to the unmodified peptide are highlighted in grey. The 
peptides carried 3 positive charges. The retention time (RT) and peak area by manual integration 
(MA) are marked. The identities of the peptides from different samples were confirmed by 
tandem MS/MS. 
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Figure 2.10  MS/MS spectra of the unmodified peptide (parental ion m/z 562.98114) from eEF-
2 in WT strain. 
 
Figure 2.11  Extracted ion chromatograms of diphthamide and diphthine from different strains. 
The peaks corresponding to diphthamide and diphthine containing peptides are highlighted in 
grey. The peptides carried 4 positive charges. The retention time (RT) and peak area integration 
(MA) were shown above the highlighted peaks.   
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Figure 2.12 MS/MS spectra of diphthamide (A, parental ion m/z 915.02325) and diphthine (B, 
parental ion m/z 915.51520) containing peptides. A neutral loss of the trimethylamino group was 
observed in both spectra and labeled b* and y*. 
We have previously reported that in P. horikoshii EF2 (PhEF-2), diphthine is not stable and 
readily eliminates the trimethylamino group and a proton in a reaction that is similar to 
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Hoffman/Cope elimination(17). This elimination is similar but different from the neutral loss of 
the trimethylamino group we observed for yeast diphthine during MS/MS. The elimination occurs 
before MS, while the neutral loss occurs during MS/MS. Two possible mechanisms for the 
elimination reaction of PhEF-2 diphthine were proposed(17). One mechanism uses an external 
base to attack the proton on the β-carbon and the other mechanism uses the carboxyl group as the 
intra-molecular base to deprotonate the β-carbon. Since the elimination reaction is species-
dependent, it is possible that the actual base is a neighboring residue that is present in PhEF-2 but 
is not present in yeast eEF-2. 
Previous genetics study provided crucial information that YBR246W is involved in diphthamide 
biosynthesis(19). However, our data presented here demonstrated that the biochemical function 
assignment was incorrect. The evidence used by Carette et al. to support that YBR246W was 
required for the first step was that eEF-2 from Δybr246w cannot be ADP-ribosylated and 
contained unmodified histidine residue. Our results demonstrated that although both observations 
can be repeated, they are only partially true. We have shown that eEF-2 from Δybr246w cannot be 
labeled when low concentration of DT was used, but can be labeled when higher concentration of 
DT was used. This labeling pattern is different from eEF-2 isolated from Δdph2 strain, which 
cannot be labeled even when higher concentration of DT was used. Our study also showed that 
unmodified eEF-2 exists even in the WT strain, consistent with a previous report(2). So the 
presence of unmodified histidine in Δybr246w does not support that the first step modification is 
impaired. Instead, it may suggest that the first step of diphthamide biosynthesis is rate-limiting. 
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The accumulation of diphthine in Δybr246w strain but not in other DPH gene deletion strains or 
WT strain demonstrated that YBR246W is required for the third step of the diphthamide 
biosynthesis. Whether YBR246W alone is sufficient for the amidation step is unknown. It is 
possible that other proteins are also required. The protein that YBR246W encodes contains WD40 
repeats which suggests that it may be a scaffold protein for the amidation step rather than a 
catalytic subunit(23, 24). Due to its scaffold role, YBR246W may be used to pull down other 
proteins required for the last step. Previous yeast genetic studies identified five DPH genes 
(DPH1-5), but YBR246W gene was not revealed. The reason is that under the selection condition 
previously used, Δybr246w was not viable to be selected, as we have shown in Figure 2.4. We 
observed that at a lower toxin induction level, the Δybr246w strain was able to grow while the 
WT strain was not. These findings may facilitate the identification of other genes involved in the 
amidation step. A recent report showed that YBR246W also functions in the retromer-mediated 
endosomal recycling pathway that is important for recycling amino acids transporters back to the 
plasma membrane(24). The fact that YBR246W functions in two apparently different biological 
pathways suggests an interesting possibility that YBR246W, as a possible scaffold protein, may 
coordinate nutrient availability (via recycling of amino acids transporters) and translation (via 
diphthamide biosynthesis). This may provide important clues to understand the function of 
diphthamide in protein biosynthesis, which has been almost completely unknown for more than 
three decades. 
Methods 
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Expression and purification of yeast eEF-2.     
The Saccharomyces cerevisiae eEF-2 with an added N/C-terminal His6 tag was cloned into p423 
MET25 vector (ATCC, Manassas, VA) as described before using the same restriction sites. The 
plasmid p423 MET25-eEF-2 (hosted by strain HL610E) was transformed into S. cereisiae strains 
with BY4741 background (OpenBiosystems, Huntsville, AL). The list of strains used in this 
study can be found in Table 2.1. To express the eEF-2 protein, the transformed cells were grown 
in synthetic complete media lacking histidine for 24 hours.  Cells were harvested by 
centrifugation and resuspended in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 mM MgCl2, 5 
mM imidazole, and 0.5 mM phenylmethylsulfonyl fluoride.  Cells were lysed using the 
EmulsiFlex-C3 cell disruptor (Avestin, Inc., Canada), and purified on BioLogic DuoFlow 10 
System (Bio-Rad, Hercules, CA). The purification was performed on HisTrap HP column (GE 
Healthcare, Piscataway, NJ) with a linear gradient from 30 mM imidazole to 500 mM imidazole 
in 30 min. The fractions were collected and dialyzed against 20 mM Tris-HCl buffer (pH 8.0) 
containing 50 mM NaCl. Protein concentration was determined by standard Bradford assay. 
Yeast growth assay.     
Cells were transformed with pLMY101 using the Frozen-EZ Yeast Transformation II Kit (Zymo 
Research, Irvine, CA). Transformed yeast cells (HL943Y – HL949Y, HL826Y – HL828Y) were 
grown on synthetic complete medium with uracil dropout. The carbon source was used as 
indicated. Colony formation was recorded 3 days after plating. 
In vitro ADP-ribosylation using Rh-NAD.   
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Rh-NAD was prepared as described previously. Purified yeast eEF-2 and Rh-NAD (50 µM) were 
incubated with DT at 30 °C in 25 mM Tris-HCl (pH 8.0), 50 mM NaCl, 30 mM dithiothreitol 
(DTT) and 2 mM ethylenediaminetetraacetic acid (EDTA). The DT concentration was 100 nM 
and the reaction time was 20 min if not specified otherwise. The reaction mixture was resolved by 
SDS PAGE. Rhodamine fluorescence signal from protein gel was visualized on a Fisher 
Scientific Ultraviolet Transilluminators.   
Rh-NAD labeling of the endogenous eEF-2.   
The yeast cell lysates were prepared as described previously. The concentration of the lysates 
were determined by Bradford assay.  The labeling was performed as described above.  The 
reaction mixture was resolved by SDS PAGE.  Rhodamine fluorescence signal from protein gel 
was visualized on a Fisher Scientific Ultraviolet Transilluminators.   
In-gel trypsin digestion of eEF-2 
The eEF-2 bands were cut from a SDS-PAGE gel. The gel bands were washed in 100 L water 
for 5 min, followed by 100 L 100 mM ammonium bicarbonate (Ambic) : acetonitrile (1:1) for 
10 min and finally 50 L acetonitrile for 5 min. The acetonitrile was then discarded and the gel 
bands were allowed to dry in a ventilated fume hood for 10-20 min. The gel slices were then 
rehydrated with 20 L of 10 mM DTT in 100 mM Ambic and incubated for 45 min at 56 °C. The 
samples were allowed to cool down to room temperature, then 20 μL of 55 mM iodoacetamide in 
100 mM Ambic was added and the samples were incubated in the dark for 60 min. Following the 
incubation, the gel slices were again washed with water, Ambic / acetonitrile and acetonitrile as 
 34 
 
described above. The gel slices were allowed to dry again. 
Gel slices were rehydrated with trypsin solution (Promega, reconstituted at 100 g/mL per 
protocol) on ice for 30 min. The trypsin solution was topped with 10 L 50 mM Ambic with 10% 
acetonitrile. The digestion reactions were kept at 30°C for 16 h. The resulting solution was 
acidified with formic acid (FA, 1% in final). The trypsin digested peptides were extracted twice 
with 30 μl of 50% acetonitrile with 5% FA (45 min incubation at room temperature followed by 5 
min sonication). The third extraction was done with 30 μl of 90% acetonitrile with 5% FA (5 
min).  All the extracts were combined and lyophilized.  
Protein Identification with nano LC/MS/MS Analysis  
The lyophilized in-gel tryptic digest samples were reconstituted in 20 L of nanopure water with 
0.5% FA for nanoLC-ESI-MS/MS analysis, which was carried out by a LTQ-Orbitrap Velos 
mass spectrometer (Thermo-Fisher Scientific, San Jose, CA) equipped with a“Plug and Play” 
nano ion source device (CorSolutions LLC, Ithaca, NY). The Orbitrap was interfaced with a nano 
HPLC carried out by Dionex UltiMate3000 RSLCnano system (Dionex, Sunnyvale, CA). The gel 
extracted peptide samples (2-4 L) were injected onto a PepMap C18 trap column-nano Viper (5 
µm, 100 µm id  2 cm, Thermo Dionex) at 20 L/min flow rate for on-line desalting and then 
separated on a PepMap C18 RP nano column (3 µm, 75 µm x 15 cm, Thermo Dionex) which was 
installed in the “Plug and Play” device with a 10-µm spray emitter (NewObjective, Woburn, MA). 
The peptides were then eluted with a 90 min gradient of 5% to 38% acetonitrile (ACN) in 0.1% 
formic acid at a flow rate of 300 nL/min. The Orbitrap Velos was operated in positive ion mode 
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with nano spray voltage set at 1.5 kV and source temperature at 275 °C.  Internal calibration was 
performed with the background ion signal at m/z 445.120025 as the lock mass. The instrument 
was performed at data-dependent acquisition (DDA) mode by one precursor ion MS survey scan 
from m/z 350 to 1800 with a resolution of 60,000  at m/z 400 followed by up to 7 MS/MS scans 
at a resolution of 7,500 on top 7 most intensive peaks subjected to high energy collision 
dissociation (HCD). Dynamic exclusion parameters were set at repeat count 1 with a 15s repeat 
duration, exclusion list size of 500, 30 s exclusion duration, and ±10 ppm exclusion mass width. 
HCD parameters were set at the following values: isolation width 2.0 m/z, normalized collision 
energy 38%, activation Q at 0.25, and activation time 0.1 ms.  All data are acquired under 
Xcalibur 2.1 operation software (Thermo-Fisher Scientific).  
Data analysis.  
Acquired MS and MS/MS raw spectra were processed using Proteome Discoverer 1.2 (PD1.2, 
Thermo) against Swissprot database with one missed cleavage site by trypsin allowed.  Mass 
tolerances for precursor ions were set at 30 ppm and for MS/MS were set at 100 mmu. A fixed 
carbamidomethyl modification on cysteine, variable modifications on methionine oxidation, 
deamindation of asparagine and glutamine, and variable substitutions on histidine including 
diphthamide and diphthine as well as the possible elimination products were specified. All 
MS/MS spectra of identified peptides were manually inspected and verified using Xcalibur 2.1 
software. 
 36 
 
Table 2.1    Yeast strains used in Chapter 2 
Strain Genotype Source 
HL813Y MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Open Biosystems   (YSC1048) 
HL814Y MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ybr246wΔ Open Biosystems  (YSC1021-552106) 
HL815Y MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 dph2Δ Open Biosystems  (YSC1021-553846) 
HL941Y MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 dph5Δ Open Biosystems  (YSC1021-552709) 
HL904Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 Open Biosystems  (YSC1049) 
HL905Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 dph1Δ Open Biosystems  (YSC1021-550206) 
HL906Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 dph2Δ Open Biosystems  (YSC1021-548861) 
HL907Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 dph3Δ Open Biosystems  (YSC1021-97228687) 
HL908Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 dph4Δ Open Biosystems  (YSC1021-549671) 
HL909Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 dph5Δ Open Biosystems  (YSC1021-547782) 
HL940Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ybr246wΔ Open Biosystems  (YSC1021-547231) 
HL823Y HL813Y [EFT1-p423MET25-HIS3] This study 
HL824Y HL814Y [EFT1-p423MET25-HIS3] This study 
HL825Y HL815Y [EFT1-p423MET25-HIS3] This study 
HL968Y HL941Y [EFT1-p423MET25-HIS3] This study 
HL943Y HL904Y [pLMY101] This study 
HL944Y HL905Y [pLMY101] This study 
HL945Y HL906Y [pLMY101] This study 
HL946Y HL907Y [pLMY101] This study 
HL947Y HL908Y [pLMY101] This study 
HL948Y HL909Y [pLMY101] This study 
HL949Y HL940Y [pLMY101] This study 
HL826Y HL813Y [pLMY101] This study 
HL827Y HL814Y [pLMY101] This study 
HL828Y HL815Y [pLMY101] This study 
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CHAPTER 3 
A CHEMOGENOMIC APPROACH IDENTIFIED YEAST YLR143W AS 
DIPHTHAMIDE SYNTHETASE 
Abstract 
Many genes are of unknown functions in any sequenced genome. A combination of chemical and 
genetic perturbations has been used to investigate gene functions. Here we present a case that 
such “chemogenomics” information can be effectively utilized to identify missing genes in a 
defined biological pathway. In particular, we identified the previously unknown enzyme, 
diphthamide synthetase, for the last step of diphthamide biosynthesis. We found yeast protein 
YLR143W is the diphthamide synthetase catalyzing the last amidation step using ammonium and 
ATP. Diphthamide synthetase is evolutionarily conserved in eukaryotes. The previously 
uncharacterized human gene ATPBD4 is the ortholog of yeast YLR143W and fully rescues the 
deletion of YLR143W in yeast.
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Introduction 
Diphthamide is a post-translationally modified histidine residue found on archaeal and eukaryotic 
translation elongation factor 2 (eEF-2)(1-3). Diphtheria toxin (DT) and Pseudomonas exotoxin A 
(ETA) recognize and ADP-ribosylate diphthamide, inhibiting eEF-2 and stopping ribosomal 
protein synthesis(4). Although diphthamide has been known for more than three decades, its 
biosynthesis and biological functions are still not completely understood. In eukaryotes, the 
diphthamide biosynthesis pathway consists of three steps (Figure 3.1)(5-9). The first step is the 
transfer of 3-amino-3-carboxypropyl (ACP) group from S-adenosyl methionine (SAM) to the 
histidine residue of eEF-2. Four proteins, DPH1-4, are required for this step in eukaryotes. The 
second step is a trimethylation reaction to form diphthine, catalyzed by a single methyltransferase 
DPH5. Both the first and the second steps have been reconstituted in vitro using purified proteins 
from a thermophilic archaea, Pyrococcus horikoshii(10-12). The third step is the amidation of 
diphthine to form diphthamide. For a long time, no proteins for the last step were identified. 
Recently, yeast YBR246W (WDR85 in human) was reported to be another protein required for 
diphthamide biosynthesis(13). We demonstrated yeast cells lacking YBR246W accumulate 
diphthine, the intermediate that is one step away from the diphthamide modifications. Therefore, 
YBR246 is required for the last amidation step(14). However, we thought it is a scaffold or 
adaptor protein instead of the actual enzyme that catalyzes the amidation reaction because it lacks 
an ATP-dependent catalytic domain. Thus, the enzyme that catalyzes the amidation step remains 
unknown even three decades after the discovery of diphthamide. 
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In Saccharomyces cerevisiae, a systematic profiling of the growth fitness of ~5000 homozygous 
gene deletion strains has been performed and the data are publically available at Yeast Fitness 
Database (http://fitdb.stanford.edu/)(15, 16). The growth was scored in response to ~400 small 
molecules and environmental stresses. The similarity of growth fitness under various conditions 
between any two different deletion strains has been calculated as the co-fitness. Two genes that 
have similar biological functions are likely to have a high co-fitness value. In this study, we 
explored the possibility of using the co-fitness data to discover the missing diphthamide 
biosynthesis gene. We found that a previously uncharacterized yeast gene YLR143W is the 
diphthamide synthetase. 
 
Figure 3.1  Biosynthetic pathway of diphthamide in eukaryotes. 
Results 
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Co-fitness analysis revealed that YLR143W is closely related to diphthamide biosynthesis 
We reasoned that the strain lacking the unknown diphthamide synthetase gene should have high 
co-fitness values with strains lacking other diphthamide biosynthesis genes. To validate this 
approach, we first analyzed the co-fitness data of ybr246w strain. The ybr246w strain has high 
co-fitness value with dph2 (0.59624, ranked #3), dph4 (0.55343, ranked #7), and dph5 
(0.57422, ranked #5) strains (Figure 3.2A). DPH3 is a fairly small ORF (249bp) and was not 
included in the original deletion strain collections. Based on the co-fitness data, it was clear that 
YBR246W has a close relation with diphthamide biosynthetic pathway. However, it was less 
clear which gene on the co-fitness list of ybr246w could be the diphthamide synthetase.  
 
Figure 3.2  The top 8 co-fitness correlations to (A) YBR246W deletion strain (B) DPH1, 2, 4 
and 5 deletion strains as a whole group. The rank of each correlation is labeled in the bottom-right 
corner. 
To provide more accurate prediction of the diphthamide synthetase gene, we reasoned that instead 
of examining the co-fitness to any individual DPH gene deletion strain, looking at the co-fitness 
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to all the DPH gene deletion strains may lead to more reliable predictions. This was done by 
adding up the co-fitness values of all homozygous deletion strains to the four DPH gene (dph1, 2, 
4 and 5) deletion strains. The grouped correlations were ranked from the highest to the lowest. 
Excluding the four DPH gene deletions strains, ybr246w had the second highest sum co-fitness 
value, showing that the sum of the co-fitness values was effective in picking up genes in 
diphthamide biosynthesis. More interestingly, ylr143w showed a higher co-fitness value than 
ybr246w to other DPH deletion strains (Figure 3.2B). ylr143w also has high co-fitness values 
with strains lacking known DPH genes (Figure 3.3). BLAST search indicated that YLR143W is 
conserved in both eukaryotes and archaea, but not in bacteria, similar to other proteins involved 
in diphthamide biosynthesis. The human ortholog is ATP-binding domain-containing protein 4 
(ATPBD4), which is consistent with the report that the amidation step of diphthamide 
biosynthesis is ATP-dependent(17). The analysis of the co-fitness data thus pointed to the 
possibility that yeast YLR143W or human ATPBD4 is the diphthamide synthetase. 
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Figure 3.3 The top 8 co-fitness correlations to YLR143W deletion strain. The rank of each 
correlation is labeled in the bottom-right corner.  
YLR143W is required for diphthine amidation in vivo 
To test whether YLR143W is indeed required for the last step of diphthamide biosynthesis, we 
first showed that yeast strain lacking YLR143W did not make diphthamide. We obtained the 
ylr143w strain and determined the modification on eEF-2 using DT and a fluorescent NAD 
analog, rhodamine-NAD (Rh-NAD). We have previously demonstrated that diphthamide can be 
labeled at both high (10 M) and low (0.1 M) DT concentrations, diphthine (from ybr246w 
strain) can only be labeled at high (10 M) DT concentration, while unmodified or ACP-modified 
eEF-2 (from dph1, dph2, dph3, dph4,or dph5 strains) cannot be labeled even at high DT 
concentration(14). When labeling purified eEF-2 from WT and mutant strains with DT and Rh-
NAD, eEF-2 from WT can be labeled at both high and low DT concentrations. In contrast, eEF-2 
from ylr143w strain can only be labeled at high DT concentration, just like the eEF-2 from 
ybr246w strain (Figure 3.4). Similar results were obtained when labeling endogenous eEF-2 in 
the crude cell extract (Figure 3.5). The data suggested that eEF-2 from ylr143w strain contains 
diphthine instead of diphthamide, similar to the eEF-2 from ybr246w.  
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Figure 3.4  Diphthine accumulates in Δylr143w yeast strain. Labeling of eEF-2 purified from 
various strains using Rh-NAD and DT. The strains are specified on top. In lane 1-4, low DT 
concentration (0.1M) was used. In lane 5-8, high DT concentration (10M) was used. 
 
Figure 3.5  The Rh-NAD labeling of total lysates from various parental strains. The parental 
strains are specified on top. The upper panel displays the eEF2 band on Coomassie Blue stained 
SDS-PAGE gel. The lower panel displays the fluorescence labeling. In lane 1-3, low DT 
concentration (0.1M)was used. In lane 4-6, high DT concentration (10 M) was used. 
We also confirmed the deficiency of diphthamide biosynthesis in ylr143w strain using an in vivo 
assay. A truncated version of DT has been used to select strains with toxin resistance(18). This 
method allowed the identification of DPH1-5(9). However, this assay was not suitable for the 
identification of YBR246W because diphthine can be ADP-ribosylated at high DT 
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concentration(14). In order to detect yeast mutants defective in the last step of diphthamide 
biosynthesis, a better assay was in need. To develop such an assay, we need a diphtheria toxin 
(DT) mutant that can differentiate diphthamide from diphthine. The wild-type DT can ADP-
ribosylate both diphthamide and diphthine and thus cannot be used in such an assay. In the 
reported structure of Exotoxin A (ETA), Asp461 forms hydrogen bond with diphthamide amide 
(Figure 3.6)(19). This is presumably the residue discriminating diphthamide and diphthine, as the 
negatively charged diphthine would be repelled by the negatively charged Asp461. In DT, this 
residue is replaced by an asparagine residue (Asn45), which may not differentiate diphthamide 
from diphthine (Figure 3.7)(20). Therefore, we thought an Asn45Asp (N45D) mutant of DT may 
be able to differentiate diphthamide from diphthine. The assay we developed also used a weaker 
GALS promoter (21) to drive the expression of the less active Asn45Asp (N45D) mutant of DT. 
The cells are transformed with plasmids containing DT mutant or wild type. The results showed 
that when strong promoter GAL1 was used, DT N55D was still too toxic (Figure 3.8A). But when 
a weaker promoter GALS was used, ybr246w strain can grow but the WT strain cannot (Figure 
3.8B). Therefore we have established a system using GALS-driven DT N45D mutant to 
discriminate diphthamide and diphthine-containing eEF-2. Similarly, ylr143w strain was able to 
grow in this assay when DT(N45D) was present, but not when wild type DT was present (Figure 
3.9 and 3.10). This in vivo assay data is consistent with the in vitro fluorescent labeling data and 
suggested that the eEF-2 from ylr143w strain contained the same modification (diphthine) as the 
eEF-2 from ybr246w strain. 
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Figure 3.6  The structure of the eEF-2-Exotoxin A complex. The picture was rendered from 
Protein Data Bank (PDB) accession code 3B78. The diphthamide on eEF-2 (green) is closed to 
D461 on Exotoxin A (blue). The distance was measured to be 2.6 angstrom.  
 
Figure 3.7  The sequence alignment of Exotoxin A and Diphtheira toxin. The diphthine 
recongnizing site is arrow-pointed. 
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Figure 3.8  Growth assay using DT mutants. (A) DT (N45D) in p426GAL1 gave no phenotypic 
difference between the wildtype (BY4741) and Δybr246w. (B) DT (N45D) in p416GALS gave 
phenotypic difference between the wildtype and Δybr246w. The parental strains used are 
specified on top. The control and toxin encoding plasmids used are specified on the right. The 
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cells were grown on 2% galactose (upper panel) or 2% glucose (lower panel).  
 
Figure 3.9  Diphtheria toxin sensitivity assay. The strains used are specified on top. Plasmids 
used in the transformation are listed on the right. The cells were grown on 2% galactose. Each 
row represents a serial dilution from left to the right. 
 
Figure 3.10  Control plates of diphtheria toxin sensitivity assay. The parental strains used are 
specified on top. The control and toxin encoding plasmids used are specified on the right. The 
cells were grown on 2% glucose. 
We further confirmed that the modification in eEF-2 from ylr143w strain is diphthine using 
mass spectrometry (MS). The peptide (686-VNILDVTLHADAIH*R-700) containing the 
modified His residue (indicated by *) from ylr143w strain has an observed m/z of 915.51245 
(doubly charged, Figure 3.11 The calculated m/z is 915.51580), while the corresponding 
diphthamide containing peptide has an m/z of 915.02351 (doubly charged)(14). The observed m/z 
value is consistent with the modification in ylr143w being diphthine. Tandem MS further 
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confirmed the modification and sequence of the peptide (Figure 3.12). Thus, all data suggested 
that eEF-2 from ylr143w strain contains diphthine. 
 
Figure 3.11  The mass spectrum of the eEF-2 peptide containing diphthine from the Δylr143w 
strain. 
 
Figure 3.12  The MS/MS spectrum of the diphthine containing peptide derived from the eEF2 
purified from ylr143w. Two neutral loss patterns were observed in the spectrum and labeled y* 
and y#.  
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YLR143W and human ortholog ATPBD4 restores diphthamide biosynthesis in ylr143w 
strain 
To confirm that the lack of diphthamide in ylr143w is indeed due to the lack of YLR143W, we 
tested whether diphthamide biosynthesis can be restored in ylr143w strain by introducing 
YLR143W back to the cells. When ylr143w was transformed with YLR143W, diphthamide can 
be detected by the labeling with low concentration of DT and Rh-NAD (Figure 3.13). 
Transformation with an empty vector failed to restore diphthamide biosynthesis. These results 
demonstrated that the lack of YLR143W was the direct cause for the lack of diphthamide 
biosynthesis in ylr143w and provided further support that YLR143W is required for the last step 
of diphthamide biosynthesis. Furthermore, human ATPBD4 can also fully restore diphthamide 
biosynthesis in ylr143w, demonstrating that human ATPBD4 is also a diphthamide synthetase 
(Figure 3.14). It is noteworthy that YLR143W is almost three times larger than human ATPBD4. 
The two proteins are similar at N-termini but YLR143W has a long C-terminal extension. The C-
terminal extension appears to be important for the proper function of YLR143W, as the truncated 
version of YLR143W failed to restore diphthamide biosynthesis (Figure 3.14).  This could be 
due to poor solubility or misfolding of truncated YLR143W. The P. horikoshii ATPBD4 
(PH1257) also failed to restore the diphthamide biosynthesis in ylr143w. We think this is likely 
because of its inability to recognize yeast eEF-2. 
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Figure 3.13  YBR246W and YLR143W restore diphthamide biosynthesis in their deletion 
strains. The deletion strains used are specified on bottom. The plasmids used are specified on top. 
The upper panel displays the lysates on Coomassie Blue stained SDS-PAGE gel. The lower panel 
displays the fluorescence labeling. In all lanes, low DT concentration (0.1 M) was used.  
 
Figure 3.14  Ectopic expression of YLR143W or human ATPBD4 restores diphthamide 
biosynthesis in the Δylr143w strain. The plasmids used are specified on top. HsATPBD4 is the 
human ATPBD4. PhATPBD4 is the ortholog from P. Horikoshii (PH1257). Low DT 
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concentration (0.1 M) was used in all lanes. 
YLR143W amidates diphthine in vitro 
To provide direct evidence that YLR143W is the enzyme catalyzing the last step of diphthamide 
biosynthesis, we reconstituted the diphthine amidation in vitro using purified proteins. The 
reconstitution reaction was carried out by incubating diphthine-containing eEF-2 with YLR143W, 
ATP, and either glutamine or ammonium chloride as the nitrogen sources. The formation of 
diphthamide was detected with Rh-NAD and low concentration of DT. As shown in Figure 3.15, 
diphthamide was formed when ammonium was used as the nitrogen source in the presence of 
both ATP and YLR143W. When glutamine was used as the nitrogen source, no diphthamide 
formation was detected. 
 
Figure 3.15  YLR143W uses ATP and NH4+ for the amidation reaction. YLR143W in vitro 
reconstitution detected using DT (0.1 M) and Rh-NAD. All reactions contain eEF-2 purified 
from the Δylr143w strain. Purified YLR143W and small molecule substrates used are indicated 
on top. 
Sequence analysis of ATP-binding domain of YLR143W revealed that it belongs to adenine 
nucleotide alpha hydrolases superfamily. The members of this superfamily include GMP 
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synthetases, argininosuccinate synthetases, and asparagine synthetases. All of these enzymes 
catalyze the cleavage of the bond between that andphosphates of ATP to form AMP as the 
end product. The P-loop-like motif SGGXD(S/T) is the signature of the ATP pyrophosphatase 
domains(22). The SGGKDS motif is strictly conserved among all the YLR143W orthologs 
(Figure 3.16). Therefore we speculated that YLR143W should form AMP in the reaction. To gain 
further insights into the catalytic mechanism of YLR143W, we determined the reaction product 
generated from ATP. -32P ATP was used to allow the detection of reaction product by 
autoradiography. Standard spots of AMP and ADP were generated by acyl-CoA synthetase and 
glutamine synthetase, respectively. We detected the formation of AMP only when YLR143W and 
eEF-2 were both present, showing that AMP is the enzymatic product (Figure 3.17). eEF-2 by 
itself generated ADP spot, probably due to its GTPase/ATPase activity(23). It is less clear why 
ADP was generated by YLR143W in the absence of eEF-2. Nevertheless, AMP was found to be 
the major product of the diphthine amidation reaction. Based on the dependence on ATP and 
NH4+ and the formation of AMP, we propose the reaction pathway for YLR143W as shown in 
Figure 3.18. 
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Figure 3.16  Clustal Omega protein sequence alignment result. The compared sequences are 
from Saccharomyces cerevisiae, Pyrococcus Horikoshii, Danio rerio, Xenopus laevis, Mus 
musculus and Homo sapiens. 
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Figure 3.17  AMP is formed in the diphthine amidation reaction. All lanes contained [-32P]-
ATP. ADP and AMP standards in lane 2 and 3 were generated enzymatically from ATP.  
 
Figure 3.18  Proposed reaction pathway for YLR143W-catalyzed diphthine amidation reaction. 
Discussion 
We have shown that the co-fitness data are powerful in discovering missing members in a 
biosynthetic pathway. Moreover, our method takes advantages of existing knowledge of the 
diphthamide biosynthetic pathway by combining the co-fitness to known DPH genes. This is an 
easy-to-perform yet reliable method as it eliminates correlations not due to functional relations. 
For example, for YBR246W, the highest correlation is to ISW1, which is the ATPase subunit of 
imitation-switch class chromatin remodelers. ISW1 has no function in diphthamide biosynthesis. 
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The reason ISW1 is showing close relation to YBR246W in the co-fitness data is that ISW1, 
which is the ORF YBR245C, is the neighboring ORF of YBR246W. Therefore the disruption of 
ISW1 may affect the integrity of YBR246W or vice versa. Such non-functional relation may give 
high pair-wise co-fitness and may lower the rank of true functional partner. In fact, YLR143W 
only ranks #13 in the correlation list of YBR246W. Fortunately, it seems that by combining the 
correlations to all the known pathway members, the missing member will stand out. We think this 
is a useful method to guide the discovery of missing pathway members. 
The physiological function of diphthamide is still not well understood. Yeast strains that lack 
diphthamide modification show no phenotype other than insensitivity to diphtheria toxin. 
However, DPH1, DPH3 and DPH4 do show important roles in mammal development(24-26). It 
has been suggested that diphthamide modification ensures translation fidelity(27, 28). Our 
correlation analysis shows that there may be a connection between diphthamide modification and 
phosphoinositide metabolism. OSH3, SCS2 and SLM1 are all on top of the correlation list. It 
would be interesting to find out whether diphthamide modification is connected to 
phosphoinositide metabolism, which may provide further insights into the function of 
diphthamide. 
The discovery of missing diphthamide synthetase may have practical implications. Exotoxin A, 
which is an ADP-ribosylating toxin like diphtheria toxin, has been used in cancer chemotherapy. 
Recent research revealed a survival strategy of cancer cells treated with exotoxin A(29). In some 
patient samples, it was found that the DPH4 promoter region can be methylated and it leads to the 
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missing of diphthamide and renders the chemotherapy inefficient(29). This was an important 
research report that helps to make better evaluation of the efficacy of the exotoxin A based 
chemotherapy. This report showed that DPH1, 2, 3 and 5 are not silenced by DNA methylation. 
However, because the knowledge of diphthamide biosynthesis pathway was not complete, we do 
not know if the epigenetic silencing happens to other diphthamide biosynthesis genes. The 
discovery of YBR246W and YLR143W as proteins required for the last step of the biosynthesis 
will be helpful to complete such studies. 
YLR143W is conserved in eukaryotes. The ortholog in humans is ATPBD4. We have shown that 
ATPBD4 can complement the loss of YLR143W in yeast, demonstrating that ATPBD4 has 
diphthamide synthetase activity. Interestingly, in a human cancer genetic study, ATPBD4 is 
found to be significantly focally deleted in all epithelial cancers. ATPBD4 is deleted in 38% of all 
lung cancer samples BD4(30). Another interesting observation was that ATPBD4 was found to be 
ubiquitylated in two independent studies(31, 32). These facts may provide crucial information to 
further understand the physiological role of ATPBD4 and diphthamide. 
In summary, we discovered the diphthamide synthetase, the enzyme that has remained unknown 
for more than 30 years after the diphthamide structure was determined. This was achieved by 
grouping the co-fitness values to all known diphthamide biosynthetic genes. Compared with the 
co-fitness analysis to an individual gene, this method provides more reliable results and is a 
powerful method to discover missing genes in defined pathways. During the preparation of the 
manuscript, we found that the alias DPH6 has been reserved on Saccharomyces Genome 
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Database, but no detail regarding the biochemical function of YLR143W was revealed. We agree 
with this naming suggestion and propose the alias DPH7 to YBR246W. 
Method 
Co-fitness analysis.     
The homozygous co-fitness data of DPH1, DPH2, DPH4, DPH5, YBR246W and YLR143W 
deletion strains were acquired from Yeast Fitness Database (http://fitdb.stanford.edu/fitdb.cgi). 
The co-fitness values were added and sorted using Microsoft Excel. The full calculation 
spreadsheet is in 
http://www.pnas.org/content/suppl/2012/11/15/1214346109.DCSupplemental/sd01.xlsx. The top 
40 lines of the added cofitness are also listed in the spreadsheet with the gene name and function 
annotations from the Saccharomyces genome database (www.yeastgenome.org). 
In vitro ADP-ribosylation using Rh-NAD.   
Rh-NAD was prepared as described previously(33). Purified yeast eEF-2 and Rh-NAD (25 µM) 
were incubated with DT at 30 °C in 25 mM Tris-HCl (pH 8.0), 50 mM NaCl, 30 mM 
dithiothreitol (DTT) and 2 mM ethylenediaminetetraacetic acid (EDTA). The DT concentration 
was 100 nM and the reaction time was 15 min if not specified otherwise. The reaction mixture 
was resolved by SDS-PAGE. The rhodamine fluorescence signal from the protein gel was 
visualized on a Fisher Scientific Ultraviolet transilluminator. 
In vitro diphthine amidation   
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Purified eEF-2 from YLR143W deletion strain was used for the amidation reaction. The eEF-2 
concentration was 0.5M and the purified YLR143W concentration was 3 nM. The reaction 
buffer contained 80 mM Tris-HCl (pH 8.0), 15 mM KCl, 5mM MgCl2, 5mM -mercaptoethanol, 
1mM ATP, 10mM NH4Cl and 0.1mg/ml BSA. Glutamine was used at 10 mM concentration as 
the potential alternative nitrogen source. The reaction was carried out at 30°C for 30min. The 
formation of diphthamide was visualized by Rh-NAD labeling as described above.  
Expression and purification of yeast eEF-2.     
The plasmid p423 MET25-eEF-2 (hosted by strain HL610E) was transformed into S. cerevisiae 
strains with BY4741 background (OpenBiosystems, Huntsville, AL). The list of strains used in 
this study can be found in Table 3.1. The expression and purification of eEF-2 was the same as 
previously reported(14). 
Rh-NAD labeling of the endogenous eEF-2.   
The yeast cell lysates were prepared as described previously(33).  The concentrations of the 
lysates were determined using absorbance at 280nm.  For each labeling reaction, the lysate was 
diluted to 10l with the final A280 of 0.16. Then the lysate and Rh-NAD (25 µM) were incubated 
with DT at 30 °C in 25 mM Tris-HCl (pH 8.0), 50 mM NaCl, 30 mM dithiothreitol (DTT) and 2 
mM ethylenediaminetetraacetic acid (EDTA).  The DT concentration was 100 nM and the 
reaction time was 15 min if not specified otherwise.  The reaction mixture was resolved by SDS-
PAGE.  Rhodamine fluorescence signal from protein gel was visualized on a Fisher Scientific 
Ultraviolet transilluminator.   
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Cloning and mutagenesis of diphtheria toxin  
The truncated diphtheria toxin was cloned from pLMY101into p426 GAL1 plasmid or others 
using primers XS182 (5'-agtcagGGATCCatgagcagaaaactgtttgcg-3') and XS183 (5'-
agtcagCTCGAGTTAcggagaatacgcgggacga-3'). The DT mutants were made by overlap extension 
PCR(34). The primers for N45D were XS180 (5'-
gccaaaatctggtacacaaggaGATtatgacgatgattggaaaggg-3') and XS181 (5'-tccttgtgtaccagattttggc-3'). 
The primers for E148S were XS178 (5'- ctgaggggagttctagcgttTCAtatattaataactgggaacaggc-3') and 
XS179 (5'- aacgctagaactcccctcag-3'). 
Yeast growth assay.     
Cells were transformed using the Frozen-EZ Yeast Transformation II Kit (Zymo Research, Irvine, 
CA).  Transformed yeast cells were grown on synthetic complete medium with uracil dropout.  
The carbon sources were used as indicated.  Colony formation was recorded 3 days after plating. 
Cloning, expression and purification of YLR143W  
Yeast YLR143W was amplified from yeast genomic DNA, which was extracted from BY4741 
using Pierce Yeast DNA Extraction Kit. The primers used were XS198 (5’- 
agtcagGGATCCATGAAGTTTATAGCATTAATATCAGG-3’) and XS199 (5’- 
agtcagGTCGACttaGGAACGAATATGCAACCCAAA -3’). The amplified gene was inserted 
into pET28a vector for protein production. The pET28a YLR143W plasmid was transformed into 
BL21(DE3) pRARE2 strain. Cells were grown in 2 liters LB medium at 37°C and 200 rpm. It 
took 4-5 hours for the OD600	 to	 reach	 0.5 after inoculation with the overnight culture. Then the 
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culturing temperature was changed to 15°C, and the protein expression was induced by 0.1 mM 
isopropyl-D-thiogalac-toside (IPTG). Cells were harvested after incubation at 15°C for 20 h. The 
protein was purified using a HisTrap column (GE Healthcare). Protein concentrations were 
determined by Bradford assay. 
32P-ATP autoradiography detecting reaction products  
To detect the product formed from ATP, the diphthine amidation reaction was performed in 10 l 
solutions with 2 Ci [-32P]-ATP (PerkinElmer, 800Ci/mmol, 2mCi/ml), 80 mM Tris-HCl (pH 
8.0), 15 mM KCl, 5 mM MgCl2, 5 mM -mercaptoethanol and 10 mM NH4Cl. The eEF-2 
concentration was 0.5 M and the purified YLR143W concentration was 0.75 M. The reactions 
were incubated at room temperature for 5 min. The ADP standard spot was generated with L-
glutamine synthetase (Sigma, G3144). The reaction contained 2 Ci [-32P]-ATP (PerkinElmer, 
800Ci/mmol, 2mCi/ml), 80 mM Tris-HCl (pH 8.0), 15 mM KCl, 5 mM MgCl2, 5 mM -
mercaptoethanol, 10 mM NH4Cl and 1 mM L-glutamate. The AMP spot was generated with acyl-
coenzyme A synthetase (Sigma, A3352). The reaction contained 2Ci [-32P]-ATP (PerkinElmer, 
800Ci/mmol, 2mCi/ml), 80 mM Tris-HCl (pH 8.0), 15 mM KCl, 5 mM MgCl2, 5 mM -
mercaptoethanol, 1 mM coenzyme A and 1 mM sodium myristate. The reactions were incubated 
at room temperature for 45 min. A total of 0.5 l of each reaction were spotted onto cellulose 
PEI-F TLC plates (Baker-flex) and developed with 2 M lithium chloride in water. After 
development, the plates were air-dried and exposed to a PhosphorImaging screen (GE Healthcare, 
Piscataway, NJ). The signal was detected using a STORM860 phosphorimager (GE Healthcare, 
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Piscataway, NJ). 
In-gel trypsin digestion of eEF-2 and nano LC/MS/MS analysis 
The in-gel digestion of eEF-2, the nano LC/MSMS analysis and associated data analysis was 
same as previously used. 
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Table 3.1    Yeast strains used in Chapter 3 
Strain Genotype Source 
HL813Y MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Open Biosystems   (YSC1048) 
HL814Y MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ybr246wΔ Open Biosystems  (YSC1021-552106) 
HL904Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 Open Biosystems  (YSC1049) 
HL940Y MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ybr246wΔ Open Biosystems  (YSC1021-547231) 
HL1025Y MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ylr143wΔ Open Biosystems  (YSC1021-552695) 
HL823Y HL813Y [p423MET25 EFT1-Histag] [1] 
HL824Y HL814Y [p423MET25 EFT1-Histag] [1] 
HL825Y HL815Y [p423MET25 EFT1-Histag] [1] 
HL968Y HL941Y [p423MET25 EFT1-Histag] [1] 
HL1026Y HL1025Y [p423MET25 EFT1-Histag] This study 
HL958Y HL904Y [p426GAL1 DT-F2] This study 
HL959Y HL904Y [p426GAL1 DT-F2 (N45D)] This study 
HL960Y HL904Y [p426GAL1 DT-F2 (E148S)] This study 
HL962Y HL904Y [p426GAL1 -] This study 
HL963Y HL940Y [p426GAL1 DT-F2] This study 
HL964Y HL940Y [p426GAL1 DT-F2  (N45D)] This study 
HL965Y HL940Y [p426GAL1 DT-F2  (E148S)] This study 
HL967Y HL940Y [p426GAL1 -] This study 
HL1008Y HL813Y [p416GALS DT-F2] This study 
HL1013Y HL814Y [p416GALS DT-F2] This study 
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Table 3.1    Yeast strains used in Chapter 3 (continued) 
Strain Genotype Source 
HL1058Y HL813Y [p416GALS DT-F2 (N45D)] This study 
HL1059Y HL813Y [p416GALS DT-F2 (E148S)] This study 
HL1060Y HL813Y [p416GALS -] This study 
HL1061Y HL814Y [p416GALS DT-F2 (N45D)] This study 
HL1062Y HL814Y [p416GALS DT-F2 (E148S)] This study 
HL1063Y HL814Y [p416GALS -] This study 
HL1064Y HL1025Y [p416GALS DT-F2] This study 
HL1065Y HL1025Y [p416GALS DT-F2 (N45D)] This study 
HL1066Y HL1025Y [p416GALS DT-F2 (E148S)] This study 
HL1067Y HL1025Y [p416GALS -] This study 
HL1039Y HL814Y [p423GAL1 YBR246W] This study 
HL1040Y HL1025Y [p423GAL1 YLR143W] This study 
HL1068Y HL814Y [p423GAL1 -] This study 
HL1069Y HL1025Y [p423GAL1 -] This study 
HL1054Y HL1025Y [p423GAL1 YLR143W-Histag] This study 
HL1055Y HL1025Y [p423GAL1 YLR143W(1-264)-Histag] This study 
HL1056Y HL1025Y [p423GAL1 ph ATPBD4-Histag] This study 
HL1057Y HL1025Y [p423GAL1 Human ATPBD4-Histag] This study 
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CHAPTER 4 
A REVISIT OF THE FUNCTION OF DPH7 
Abstract 
Diphthamide biosynthesis is a stepwise process. The current model is that three steps are involved. 
We found that although both dph6 and dph7 accumulate diphthine intermediate, the two 
diphthine-containing intermediates are not the same. The eEF-2 from dph6 can be amidated by 
purified Dph6 but eEF-2 from dph7 cannot be amidated by purified Dph6, although both types 
of eEF2 contain the diphthine modification. Therefore, there must be one more step in 
diphthamide biosynthesis that requires Dph7. Dph7 catalyzes or helps catalyze the reaction 
between Dph5 and Dph6. The exact nature of the distinction of the two diphthine-containing eEF-
2 is not clear. A few possibilities are discussed in the end of this chapter.
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Introduction 
Diphthamide is a post-translationally modified histidine residue found in eukaryotic and archael 
elongation factor 2(1-4). It is the target of diphtheria toxin produced by Corynebacterium 
diphtheriae(5). Diphtheria toxin (DT) catalyzes the ADP-ribosylation reaction on the 
diphthamide residue of EF-2 using NAD as the ADP-ribose donor. The ADP-ribosylated EF-2 is 
inactive and unable to catalyze the translocation step in the ribosomal protein synthesis. 
diphthamide is one of the most complicated post-translational modifications. It has been thought 
to involve three enzymatic steps in and seven proteins(6-17). Dph1-4 are required for the first 
step, which is the transfer of the 3-amino-3-carboxypropyl (ACP) group. The second step requires 
Dph5 which is a methyltransferase that produces diphthine intermediate. Dph6 is the diphthamide 
synthetase that uses ATP and amidates diphthine to give diphthamide.  
In the previous chapters, we have been able to show that Dph6 is the diphthamide synthetase, 
which catalyzes the amidation step converting diphthine into diphthamide. However, little was 
explored on the biochemical function of Dph7. Dph7 was identified in a genetic screening in 
which human WDR85, which is homolog of yeast Dph7, and was shown to be required for the 
first step of diphthamide biosynthesis(15). Later discovered that Dph7 is required for diphthine 
amidation, since dph7 accumulates diphthine intermediate(16). This result suggests that Dph7's 
function is a prerequisite for the diphthine amidation reaction. So there are several possibilities 
about Dph7's function. One of them is that Dph7 may enhance the activity of Dph6. Dph7 has a 
WD40-repeat domain, which is thought to mediate protein-protein interaction(18). Dph7 may 
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work as a Dph6 binding partner and promotes its activity. Interestingly, our work shows that this 
model is not correct. Our data suggest that Dph7 is responsible for one more enzymatic step in the 
diphthamide biosynthesis pathway. The exact nature of this conversion is not yet clear. 
Nevertheless, our results suggest that diphthamide biosynthesis has a minimum of four steps. 
Results 
eEF-2 from dph7 cannot be amidated by Dph6.  
In the previous chapter, we have shown that the diphthine-containing eEF-2 can be in vitro 
amidated by purified Dph6. However, in that experiment, the eEF-2 was purified from dph6. To 
determine if there is any difference on the eEF-2 purified from dph6 and dph7, we used both 
of them in the amidation reaction as substrates. DT was used at low concentration to detect the 
formation of diphthamide after the amidation step. To our surprise, only the eEF-2 from dph6 
was amidated but not the one from dph7 (Figure 4.1). This result means that there are actually 
two diphthine-containing eEF-2 species, one can be amidated but not the other one. This was a 
surprising result. The eEF-2 proteins from dph6 and dph7 are quite similar. They have been 
shown to have diphthine by mass spectrometry and they have similar activity working as DT's 
substrate. The ability to serve as Dph6's substrate is their only distinction that we know. 
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Figure 4.1 eEF-2 from dph7 cannot be amidated by purified Dph6. Purified eEF-2 was used in 
this experiment and the sources from which the eEF-2 was purified is specified on top. The lower 
panel displays the eEF-2 band on Coomassie Blue stained SDS-PAGE gel. The upper panel 
displays the fluorescence labeling. Low DT concentration (0.1M) was used in this assay.  
In vitro preparation of diphthine-containing eEF-2 using Dph5.  
In the originally proposed diphthamide biosynthetic pathway, there is no room for two diphthine-
containing eEF-2 species. Therefore, this pathway needs to be revised. To determine at which 
step the Dph7 activity is required, we took a step back to carry out the methylation step in vitro to 
make diphthine-containing eEF-2. 
Dph5 was cloned into pET28a vector and was expressed and purified from E. coli (Figure 4.2). 
The activity of Dph5 was first tested using eEF-2 purified from dph5, which is ACP-modified 
(Figure 4.3). When provided with Dph5 and SAM, diphthine was generated as it can be labeled 
with high concentration of DT. There was no sign of the elimination of the trimethylamino group 
even when high concentration of SAM was used. The elimination reaction has been reported to 
happen on PhEF-2(19). As we have discussed in the previous chapter, it seems that diphthine on 
yeast eEF-2 is much more stable. The stability of diphthine on yeast eEF-2 allows the detection of 
diphthine as an intermediate in the diphthamide biosynthesis. Here we show again that excess of 
SAM does not lead to the elimination of the trimethylamino group. 
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Figure 4.2 Dph5 purified from E. coli. The calculated mass of His6-tagged Dph5 is 38kDa. 
 
Figure 4.3 Activity assay of purified Dph5. eEF-2 purified from dph5 was used as the substrate. 
The lower panel displays the eEF-2 band on Coomassie Blue stained SDS-PAGE gel. The upper 
panel displays the fluorescence labeling. High DT concentration (10M) was used in this assay to 
detect the formation of diphthine. The SAM concentration in the reaction was 30 M (lane 1), 50 
M (lane 2), 100 M (lane 3), 300 M (lane 4), 500 M (lane 5), 1 mM (lane 6), 3 mM (lane 7). 
Diphthine generated from Dph5 cannot be amidated 
The next step was to determine as which point the Dph7 activity is needed. It is obvious that 
Dph6 is the last step of diphthamide biosynthesis as the product from this step is diphthamide. 
Dph7, however, may work before or after Dph5. We are not clear about the nature of Dph7 
catalyzed reaction. We may assume that Dph7 catalyzes a phosphorylation reaction on eEF-2. 
And Dph6's recognition of eEF-2 as a substrate depends on this phosphorylation, while the non-
phosphorylated eEF-2 is acceptable by Dph1-5, then without Dph7 the eEF-2 could only be 
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diphthine-modified. The Dph7 catalyzed phosphorylation may work upstream of Dph5 or even 
Dph1-4. Therefore, to determine the reaction order, we tried to use Dph5 generated diphthine as a 
substrate for Dph6 amidation. In this experiment, the eEF-2 was isolated from dph5, so that 
Dph7 was in that strain. If there is a reaction that can be done by Dph7 upstream of Dph5, it must 
have been done. In that case, the in vitro trimethylated eEF-2 should be able to work as Dph6's 
substrate. Our experimental results showed the opposite. When provided Dph5, Dph6 and other 
small molecule co-substrates, the eEF-2 can only be labeled by high concentration of DT. It 
means that only diphthine was formed. Diphthamide was not generated from this reaction, 
suggesting that Dph7's activity is required after the action of Dph5. 
 
Figure 4.4 Amidation assay of diphthine produced by Dph5. eEF-2 purified from dph5 was 
used as the substrate. The lower panel displays the eEF-2 band on Coomassie Blue stained SDS-
PAGE gel. The upper panel displays the fluorescence labeling. Low (0.1M) and high DT 
concentration (10M) was used in this assay to detect the formation of diphthamide and diphthine. 
The components used in the reactions are indicated on top of the gel. 
Discussion 
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Previous study only identified three steps in diphthamide biosynthetic pathway. We have 
identified yeast ORF YLR143W (Dph6) as the diphthamide synthetase. In this chapter, we 
showed that there are actually two diphthine-containing eEF-2 species, one can be converted to 
diphthamide by Dph6 and the other one cannot. Dph7 works after Dph5, converting the non-
amidatable diphthine to the amidatable form. We are trying to reconstitute this step in vitro using 
purified Dph7, which may provide more information regarding this reaction and the biochemical 
function of Dph7. 
There are two possibilities about the two diphthine-containing eEF-2 species. One is that their 
distinction is post-translational modification on a different site on eEF-2. The other possibility is 
the two diphthine are structurally not the same. There has been no sufficient evidence to support 
either one. We do notice one report though, in which the configuration of diphthamide is thought 
to be different from previously reported(20). The ACP group of diphthamide comes from 
methionine(6). Therefore the chiral carbon on the side chain of diphthamide has been assigned S 
configuration. However, crystallography study suggested the R configuration on the third carbon 
of diphthamide side chain (Figure 4.5)(21). If this result is true, there may be an isomerization 
step to convert S-diphthine to R-diphthine, then the R-diphthine is amidated to give R-
diphthamide. In this case, the function of Dph7 is to catalyze this isomerization reaction (Figure 
4.6).  
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Figure 4.5  Structure of diphthamide on eEF-2 (Rendered from PDB 3B82) may be in R-
configuration. 
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Figure 4.6  Proposed diphthamide biosynthetic pathway. 
Other possibilities exist regarding the identity of two diphthine-containing eEF-2 species. For 
example, the addition or removal of a post-translational modification on a different residue of 
eEF-2. Again, the reconstitution of the Dph7-catalyzed step may help to elucidate this. If a 
phosphorylation or acetylation is involved, ATP or acetyl-CoA would be required as the co-
substrate. And MS study on eEF-2 would reveal the site of this modification. 
Methods 
In vitro ADP-ribosylation using Rh-NAD.   
Rh-NAD was prepared as described previously(22). Purified yeast eEF-2 and Rh-NAD (25 µM) 
were incubated with DT at 30 °C in 25 mM Tris-HCl (pH 8.0), 50 mM NaCl, 30 mM 
dithiothreitol (DTT) and 2 mM ethylenediaminetetraacetic acid (EDTA). The DT concentration 
was 10 M and the reaction time was 60 min if not specified otherwise. The reaction mixture was 
resolved by SDS-PAGE. The rhodamine fluorescence signal from the protein gel was visualized 
on a Fisher Scientific Ultraviolet transilluminator. 
Cloning, expression and purification of Dph5 
Yeast Dph5 was amplified from yeast genomic DNA, which was extracted from BY4741 
using Pierce Yeast DNA Extraction Kit. The primers used were XS221 (5’- 
agtcagGGATCCatgctttatttgatcggacttg-3’) and XS220 (5’-
agtcagGTCGACttactcgtcgctgtcgtcttct-3’). The amplified gene was inserted into pET28a 
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vector for protein production. The pET28a Dph5 plasmid was transformed into BL21 
pRARE2 strain. Cells were grown in 2 liters LB medium at 37°C and 200 rpm. It took 4-
5 hours for the OD600	 to	 reach	0.5 after inoculation with the overnight culture. Then the 
culturing temperature was changed to 15°C, and the protein expression was induced by 
0.1 mM isopropyl-D-thiogalac-toside (IPTG). Cells were harvested after incubation at 
15°C for 20 h. The purification using HisTrap column (GE Healthcare) is the same as 
eEF-2 protein. Protein concentrations were determined by Bradford assay. 
In vitro eEF-2 methylation 
Purified eEF-2 from DPH5 deletion strain was used for the methylation reaction. The eEF-2 
concentration was 0.5M and the purified Dph5 was used at a concentration of 1M. The 
reaction buffer contained 80 mM Tris-HCl (pH 8.0), 15 mM KCl, 5mM MgCl2, 5mM -
mercaptoethanol and various concentration of SAM as indicated. The reaction was carried out at 
30°C for 40min. The formation of diphthine was visualized by Rh-NAD labeling as described 
above.  
In vitro eEF-2 methylation and amidation 
Purified eEF-2 from DPH5 deletion strain was used for the methylation and amidation reaction. 
The eEF-2 concentration was 0.5M and the purified Dph5 and Dph6 were used at a 
concentration of 1M. The reaction buffer contained 80 mM Tris-HCl (pH 8.0), 15 mM KCl, 
5mM MgCl2, 5mM -mercaptoethanol, 1mM ATP, 10mM NH4Cl and 300M SAM. The 
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reaction was carried out at 30°C for 40min. The formation of diphthine/diphthamide was 
visualized by Rh-NAD labeling as described above. 
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CHAPTER 5 
FUNCTIONAL STUDIES OF YEAST DPH1-4 
Abstract 
The most complicated step of diphthamide biosynthesis in eukaryotes is the first step, which is 
the transfer of 3-amino-3-carboxylpropyl (ACP) group onto the histidine residue on eEF-2. 
Several approaches were taken to study the reaction mechanism in greater details. By using an in 
vivo activity assay of Dph1 and Dph2, we have discovered 3 and 2 catalytically important 
cysteine residues in Dph1 and Dph2 respectively. Dph1 and Dph2 were co-expressed and purified. 
The resulting Dph1/Dph2 complex is active in SAM cleavage and generates 5'-deoxy-5'-
methylthioadenosine. Dph3 has also been expressed and purified. It can bind iron and is redox-
active. Unfortunately, the reconstitution of the first step reaction using purified proteins has not 
been successful, making it challenging to study the function of each protein in detail. 
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Introduction 
In the previous chapters, we have been focusing on later steps of diphthamide biosynthetic 
pathway. In eukaryotes, the most complicated step is probably the first step, which is the transfer 
of the 3-amino-3-carboxylpropyl (ACP) group onto the histidine residue on eEF-2(1-8). The 
mechanism of this step has been extensively studied in an archaeal system(9, 10). The archaeal 
species Pyrococcus horikoshii, unlike yeast, has only one identifiable gene to catalyze this step. 
The Pyrococcus horikoshii Dph2 (PhDph2) is homologous to eukaryotic Dph1 and Dph2. Crystal 
structure of PhDhp2 revealed a homodimeric organization and the coordination of one [4Fe-4S] 
cluster per monomer. PhDph2 lacks the CX3CX2C motif which is the signature of canonical 
radical SAM enzymes, but contains three conserved cysteine residues Cys59, Cys163 and Cys287 
that are spatially close and coordinate the [4Fe-4S] cluster. PhDph2 cleaves the C,Met–S bond of 
SAM to form 5'-deoxy-5'-methylthioadenosine (MTA) and ACP radical. The ACP radical 
performs hydrogen abstraction on the C-2 position of the imidazole ring to give the final 
product(9, 10).  
The yeast system, however, is more complicated than the archaeal system. There are four gene 
Dph1-4 that are found to be required for the first step(7, 8). Dph1 and Dph2 are homologous to 
PhDph2(11). There is no homolog of yeast Dph3 and Dph4 in Pyrococcus horikoshii. Based on 
the fact that PhDph2 alone is sufficient to catalyze the first step of diphthamide biosynthesis in 
Pyrococcus horikoshii, we assume that Dph1/Dph2 are the catalytic components for the first step 
diphthamide biosynthesis in eukaryotes. Dph3 and Dph4 may have some auxiliary roles. In this 
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chapter, we present data showing that Dph1 and Dph2 complex is active in generating MTA and 
ACP radical, but failed to perform the transfer of the ACP group to eEF-2. Dph3 was found to 
bind iron. E. coli. riboflavin reductase NorW is able to reduce the iron on Dph3 in a NADH-
dependent manner. 
Results 
Sequence alignment of Dph1/Dph2 and PhDph2 
Yeast Dph1 and Dph2 are homologous to PhDph2. The sequence alignment shows that 
eukaryotic Dph1 has higher similarity to PhDph2 (Figure 5.1). There are three cysteine residues 
in PhDph2 that coordinate the [4Fe-4S] cluster, Cys59, Cys163 and Cys287. The corresponding 
residues are Cys133, Cys239 and Cys368 in yeast Dph1. In yeast Dph2, Cys106 and Cys362 
correspond to PhDph2 Cys59 and Cys287. There is no cysteine in yeast Dph2 that corresponds to 
PhDph2 Cys163. The conserved cysteine pattern implies an asymmetry of the Dph1/Dph2 
heterodimer. In PhDph2, it has been shown that only one of the two monomers is required for the 
full activity. Yeast Dph1 has the three conserved cysteine residues to bind the [4Fe-4S] cluster 
and has higher homology to PhDph2, therefore Dph1 maybe more important for the catalysis. 
Yeast Dph2 has only two out of the three conserved cysteine residues. So the function of Dph2 
may not be the same as the Dph1.  
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Figure 5.1 Sequence alignment of Dph1 and Dph2 proteins from different species. Black arrows 
indicate the cysteine residues that bound the [4Fe-4S] cluster in PhDph2.  
Mutagenesis of Dph1/Dph2 revealed important cysteine residues 
To study the function of Dph1 and Dph2 in greater detail, we first did the mutagenesis study on 
Dph1/Dph2. Various Dph1 or Dph2 mutants were constructed and introduced back into the Dph1 
or Dph2 deletion background, respectively. If the mutated residue is not important, the mutant 
would retain activity and restore the generation of diphthamide in the Dph1 or Dph2 deletion 
background. The restoration of diphthamide biosynthesis can be detected by diphtheria toxin (DT) 
sensitivity assay. Dph2 mutants were studied first (Figure 5.2). The results showed that Dph2 
C362A mutants failed to restore DT sensitivity while C106A mutant succeeded. Therefore 
Cys362 is required for Dph2's activity but not the Cys106. We noticed the presence of Cys107 in 
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Dph2 so we tried C107A mutant too. The results showed that Cys107 is indeed required for 
Dph2's activity (Figure 5.2). The Dph1 mutants have also been studied. Cys133, Cys239 and 
Cys362 in yeast Dph1 are shown to be required for activity. These are the residues conserved 
from PhDph2 to yeast Dph1.  
 
Figure 5.2  Mutagenesis study of Dph2. Mutants or wt DPH2 gene were inserted into p413Gal1 
plasmid which was used to transform the dph2 strain together with the pLMY101 plasmid 
encoding DT. The DT sensitivity was evaluated on 2% Galactose medium. The plasmids used are 
specified on the left side. The spots from right to left represent a serial dilution. 
 
Figure 5.3  Mutagenesis study of Dph1. Mutants or wt DPH1 gene were inserted into p413Gal1 
plasmid which was used to transform the dph1 strain together with the pLMY101 plasmid 
encoding DT. The DT sensitivity was evaluated on 2% Galactose medium. The plasmids used are 
specified on the left side. The spots from right to left represent a serial dilution. 
The mutagenesis study not only revealed the important cysteine residues but also show that both 
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Dph1 and Dph2 are required for the first step reaction of diphthamide biosynthesis. In PhDph2, a 
chimeric heterodimer which has one active monomer and one inactive monomer is functional. 
But in yeast Dph1/Dph2, a point mutation in Dph2 makes the heterodimer inactive. Therefore, the 
catalytic mechanism of yeast Dph1/Dph2 must be different from PhDph2. 
Expression and purification of yeast Dph1/Dph2 
To study how Dph1/Dph2 catalyze the first step biosynthesis, we aimed to express the proteins 
and reconstitute the activity in vitro. We first cloned Dph1/Dph2 genes into pDEST expression 
vectors with either N-His6 or N-His6-MBP (maltose-binding protein) fusions using Gateway 
technologies (Invitrogen). From the E. coli expression, Dph1 and Dph2 cannot give soluble 
protein when singly expressed. Considering that the complex they form may have better stability 
and solubility, we also tried to co-express these two proteins using the Duet vectors (Novagen). 
The Dph1/Dph2 can be expressed from the pET duet vector but the level was not high. Later, we 
moved the multiple cloning site region of pET duet-1 containing Dph1 and Dph2 to pET28b and 
the expression was greatly improved (Figure 5.4). In order to make Dph1/Dph2 active, Fe and 
cysteine were supplemented to the growth medium when culturing cells. Dph1/Dph2 was also 
purified under anaerobic condition. 
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Figure 5.4 Expression and purification of yeast Dph1-Dph2 in pET duet-1 (A) and pET28b (B). 
A higher expression level was achieved in pET28b vector. Proteins were purified by Ni-affinity 
purification. For each panel, the left lane shows the protein ladder and the right shows the purified 
Dph1/Dph2. 
Characterization of Dph1/Dph2 and the activity assay 
Before testing the enzymatic activity of Dph1/Dph2, the iron-sulfur cluster was characterized first. 
The iron content was measured to be 1.2 per monomer and the sulfur content was measured to be 
0.6 per monomer. To better characterize the iron-sulfur cluster on Dph1/Dph2, the UV spectra 
were taken. The oxidized form of [4Fe-4S] cluster shows absorbance at 410nm. Our result 
showed that Dph1/Dph2 indeed has absorbance at 410nm. When reduced with dithionite, the 
410nm absorbance decreased.  
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Figure 5.5 The UV spectra of Dph1/Dph2. The blue and black lines are showing the background. 
The green line is showing the absorbance of Dph1/Dph2, and the red line is showing the 
Dph1/Dph2 after the dithionite reduction. 
The first step of PhDph2 catalyzed reaction is the cleavage of SAM to generate MTA. We were 
able to show that the Dph1/Dph2 is capable of catalyzing the same reaction. Dph1/Dph2's activity 
depends on the presence of dithionite. 5'-deoxyadenosine is not a product from Dph1/Dph2 
catalyzed SAM cleavage. 
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Figure 5.6 Purified yeast Dph1-Dph2 can cleave SAM. The reaction products were analyzed on 
HPLC to detect the formation of MTA. MTA production is dependent on Dph1-Dph2 and 
dithionite. 
Expression, purification and characterization of Dph3 and Dph4 
We assume that Dph1/Dph2 in vitro are sufficient to catalyze the transfer of the ACP group. 
However, we also cloned, expressed and purified yeast Dph3 and Dph4 to study their function. 
The Dph3/Dph4 genes were cloned into pDEST expression vectors with either N-His6 or N-His6-
MBP (maltose-binding protein) fusions using Gateway technologies (Invitrogen). The MBP tag 
was removed by using TEV protease. Dph3 and Dph4 were expressed in BL21R2 cells and 
purified (Figure 5.7). 
Dph3 showed purple color after the purification, implying the coordination with iron. To confirm 
it, we took the UV spectra of Dph3. Dph3 showed absorbance at 495nm. When reduced with 
dithionite, the 495nm absorbance decreased and the color was gone. The reduced Dph3 can be 
slowly re-oxidized in air (Figure 5.8). Dph4 has no color after purification. 
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Figure 5.7 Expression and purification of yeast Dph3 and Dph4. Proteins were purified by Ni-
affinity purification. The left lane shows the protein ladder and the right lanes show the purified 
Dph3 and Dph4. 
 
Figure 5.8 The UV spectra of Dph3. The pink trace is showing the absorbance of Dph3. The 
green trace is showing the Dph3 after dithionite reduction. The red trace is showing the Dph3 re-
oxidized in air. 
We have also confirmed that Dph3 can be reduced by riboflavin reductase NorW. NorW was 
cloned and expressed in E. coli. NorW showed bright yellow color, indicating the presence of 
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flavin adenine dinucleotide (FAD). When incubated with NorW and NADH, Dph3 can be quickly 
reduced (Figure 5.9).  
 
Figure 5.9 Dph3 characterized by UV-Vis spectroscopy. The pink trace was Dph3 and the green 
trace was Dph3 reduced by 1mM dithionite. The reaction was then open to air for 20 minutes. 
The red trace shows the absorbance after the incubation. 
Reconstitution of the ACP transfer reaction 
Attempts were made to reconstitute the ACP transfer reaction. To monitor this reaction, carboxyl-
14C-SAM was used as the co-substrate. Purified Dph1-4 and eEF-2 was used. All proteins were 
desalted using anaerobic buffer. Unfortunately, no 14C labeling on eEF-2 was detected (Figure 
5.10). There may be many reasons for it. The primary concern was the concentration and/or 
quality of eEF-2. 
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Figure 5.10 The 14C labeling assay of eEF-2. The left panel displays the protein bands on 
Coomassie Blue stained SDS-PAGE gel. The right panel displays the autoradiography from 14C. 
Lane 1 contained Dph1-4 and eEF-2. Lane 2 contained Dph1-2 and eEF-2. Lane 3 contained 
another batch of Dph1/Dph2 as well as Dph3/4 and eEF-2. 
Discussion 
Our hypothesis is that Dph1 and Dph2 form a heterodimer (Dph1-Dph2) that is equivalent to the 
homodimer of PhDph2. Dph1 and Dph2 are homologous to each other and has been reported to 
form a complex(8). The function of Dph3 and Dph4 is probably involved in assembly of the Fe-S 
cluster or transferring electron to the Fe-S cluster in Dph1-Dph2. However, exactly what they do 
and how they do it is unknown. Our preliminary data suggest that the enzymology of Dph1-Dph2 
is different and much more complicated than that of PhDph2. For the PhDph2 homodimer, we 
found that only one of the subunits is required to have a [4Fe-4S] cluster. A PhDph2 heterodimer 
with one wt subunit and one C59A/C287A double mutant (cannot bind Fe-S cluster) is still able 
to catalyze the reaction in vitro with efficiency undistinguishable from that of wt PhDph2 
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homodimer. In contrast, in our in vivo studies with yeast Dph1 and Dph2, we found that each of 
them have three Cys residues that are required for activity. In Dph1, the three Cys residues (C133, 
C239, C368) are equivalent to the three Cys residues in PhDph2 (C59, C163, C287) that bind the 
Fe-S cluster. The required Cys residues in Dph2 are C107 and C362. C362 in yeast Dph2 is 
equivalent to C287 in PhDph2, but C107 in yeast Dph2 is only conserved in eukaryotic Dph1 and 
Dph2 proteins but not in archaeal Dph2. Thus it seems that Dph1-Dph2 is different from the 
PhDph2 homodimer. We suspect that the electron transfer chemistry in eukaryotic Dph1-Dph2 
may be different from that in PhDph2. It should be pointed out that conserved and/or catalytically 
important Cys residues should never be overlooked, as recent work by Dr. Squire Booker and 
coworkers on the ribosomal RNA methylating enzymes RlmN and Cfr discovered an extremely 
interesting methylation mechanism by radical SAM enzymes(12, 13). Therefore, we think 
eukaryotic Dph1-Dph2 is worth studying in great details. The Dph1/Dph2 we prepared has been 
shown to be active in SAM cleavage, therefore it is most likely that the Fe-S cluster was in an 
active form. However, the Dph1/Dph2 failed to show activity in catalyzing the ACP transfer. 
There could be many reasons to it, and the primary concern is the concentration/quality of the 
yeast eEF-2. We have tried to express and purify yeast eEF-2 from E. coli but failed.  
Our hypothesis about Dph3 is that it is an electron carrier that mediates the reduction of the Fe-S 
clusters in Dph1-Dph2. This is supported by our and others’ finding that it can bind iron with four 
conserved Cys residues and is redox active(14). This can also explain why Dph3 is required for 
certain tRNA modifications that require another radical SAM enzyme Elp3, because Dph3 could 
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also be responsible for reducing the Fe-S cluster in Elp3(15).  
Dph4 contains four conserved Cys residues similar to Dph3. In addition, it has a J domain that is 
found in many co-chaperon proteins(16, 17). We hypothesized that the function of Dph4 is to 
help assemble the Fe-S clusters in Dph1-Dph2. This hypothesis is based on the similarity of Dph4 
with human HscB. Human HscB has an N-terminal tetra-Cys motif, and a C-terminal J 
domain(18, 19). In contrast, Dph4 has an N-terminaI J domain and a C-terminal tetra-Cys motif. 
HscB is conserved in most species, including bacteria. However, the bacterial HscB and the yeast 
homolog Jac1 both lack the tetra-Cys motif. In bacteria, it is known that HscB is a co-chaperon 
that interacts with the chaperon protein HscA, and the two together help to transfer the Fe-S 
cluster assembled on IscU to apo Fe-S cluster proteins. Thus, the function of Dph4 is probably 
similar to bacterial HscB, functioning with a chaperon protein to transfer Fe-S clusters to apo Fe-
S proteins in the cytosol, either non-specifically to multiple proteins or specifically to Dph1-Dph2. 
In contrast, human HscB or yeast Jac1 is the mitochondrial co-chaperon for transferring Fe-S 
clusters to apo Fe-S proteins in the mitochondria. 
Methods 
Cloning, expression of Dph1 and Dph2 
Yeast Dph1 and Dph2 was amplified from yeast genomic DNA, which was extracted from 
BY4741 using Pierce Yeast DNA Extraction Kit. The primers used for Dph1 were XS022 (5’- 
agtcaggaattcTATGAGTGGCTCTACAGAATC-3’) and HL002 (5’- 
agtcaggtcgacCTATTCAATCGCATGTTTCGG -3’) and the primers used for Dph2 were XS035 
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(5’-agtcagCATATGATGcaccatcaccaccatcatcaccatGAAGTTGCACCGGCCTT-3’) and XS004 
(5’- agtcagGGTACCtcatttgttttcctttttcatagc-3’). Dph2 was inserted into pETduet-1 vector first, 
followed by the insertion of Dph1. The Dph1/Dph2 part from pETduet-1 was also amplified 
using primers XS022 and XS004 and transferred to the pET28b vector. The plasmids pET28duet-
1 Dph1/Dph2 and pET28b Dph1/Dph2 were used to transform BL21(DE3) pRARE2 strain 
respectively. Cells were grown in 2 liters LB medium at 37°C and 200 rpm. It took 4-5 hours for 
the OD600	 to	 reach	 0.5 after inoculation with the overnight culture. The cultures were 
supplemented with FeCl3, Fe(NH4)2(SO4)2 and L-cysteine to final concentrations of 50 μM, 
50 μM and 400 μM, respectively. Then the culturing temperature was changed to 15°C, and the 
protein expression was induced by 0.1 mM isopropyl-D-thiogalac-toside (IPTG). Cells were 
harvested after incubation at 15°C for 20 h.  
Anaerobic purification of Dph1 and Dph2 
Purification of Dph1/Dph2 was performed in an anaerobic chamber (Coy Laboratory Products). 
Cell pellet from 2 liter culture was resuspended in 30 mL lysis buffer (500 mM NaCl, 10 mM 
MgCl2, 5 mM imidazole, 1 mM DTT, 0.3% (w/v) lysozyme and 20 mM Tris-HCl at pH 7.4). 
Cells were incubated at 25 °C for 1 h, followed by liquid nitrogen freezing and then thawed at 
25 °C. Cell debris was removed by centrifugation at 48,000g (Beckman Coulter Avanti J-E) for 
30 min. The supernatant was incubated for 1 h with 1.2 ml Ni-NTA resin (Qiagen) pre-
equilibrated with the lysis buffer (without lysozyme). The resin after incubation was loaded onto 
a polypropylene column and washed with 20 ml lysis buffer (without lysozyme). Dph1/Dph2 was 
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eluted from the column with elution buffers (100 mM or 150 mM imidazole in the lysis buffer, 
1.5 ml each). The brown-coloured elution fractions were buffer-exchanged to 150 mM NaCl, 
1 mM DTT and 200 mM Tris-HCl at pH 7.4 using a Bio-Rad 10-DG desalting column. Protein 
concentrations were determined by Bradford assay. 
Mutagenesis of Dph1 and Dph2  
Yeast Dph1/Dph2 were cloned into p413GAL1 vector for the in vivo activity assay. Dph1 gene 
was amplified from pETduet-1 Dph1/Dph2 vector using primers MVG003 (5'-
acgtcgACTAGTATGAGTGGCTCTACAGAATCTA-3') and MVG004 (5'-
acgtcgCTCGAGCTATTCAATCGCATGTTTCGGA-3'). Dph2 gene was amplified from 
pETduet-1 Dph1/Dph2 vector using primers HL004 (5’-
agtcagctcgagTCATTTGTTTTCCTTTTTCATAGC-3’) and HL008 (5’-
agtcagactagtATGGAAGTTGCACCGGCCTT-3’). The mutations were made by overlap 
extension PCR. The primers for Dph1 C133A were XS005 (5’-
ggatgtgtcttatggtgcaGCCtgtattgatgattttactgctag-3’) and XS006 (5’- tgcaccataagacacatccc-3’). The 
primers for Dph1 C239A were XS007 (5’- gaggggtgaagtattggggGCTacttctgaaagattagataaaga-3’) 
and XS008 (5’-ccccaatacttcacccctc-3’). The primers for Dph1 C368A were XS009 (5’-
gatgtttttgttcaggtcgcaGCTcctagactgtccatcgattg 
-3’) and XS010 (5’- tgcgacctgaacaaaaacatc -3’). The primers for Dph2 C107A were XS011 (5’-
cacagcgtacagtgcatgcGCTgtagacgaggtcgctgctg-3’) and XS012 (5’-gcatgcactgtacgctgtg-3’). 
The primers for Dph1 C118A were XS015 (5’- cattttggaacagttcGCTggtgttgaaactctag-3’) and 
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XS016 (5’- ctagagtttcaacaccAGCgaactgttccaaaatg -3’). The primers for Dph1 C134A were 
XS013 (5’-gatgtgtcttatggtgcatgcGCTattgatgattttactgctagg-3’) and XS014 (5’- 
ctagcagtaaaatcatcaatAGCgcatgcaccataagacacatcc -3’). The primers for Dph1 C145A were XS017 
(5’-gctagggcattggatGCCgattttattgtgcattacg-3’) and XS018 (5’- 
cgtaatgcacaataaaatcGGCatccaatgccctagc -3’). The primers for Dph1 C155A were XS019 (5’- 
gcattacgctcattcgGCTttagttcctattgacg-3’) and XS020 (5’-cgtcaataggaactaaAGCcgaatgagcgtaatgc -
3’).  
Yeast growth assay.     
Cells were transformed with the Dph1 or Dph2 encoding plasmid together with the pLMY101 
plasmid which encodes the diphtheria toxin using the Frozen-EZ Yeast Transformation II Kit 
(Zymo Research, Irvine, CA). Transformed yeast cells were grown on synthetic complete 
medium with histidine and uracil dropout with 2% glucose as the carbon source. For the survival 
assay 2% galactose was used as the carbon source.  Colony formation was recorded 3 days after 
plating. 
Analyzing reaction product from Dph1/2 with high-performance liquid chromatography 
Under anaerobic conditions, reactions were assembled with 30 μM Dph1/Dph2, 30 μM SAM, 
10 mM dithionite, 150 mM NaCl, 1 mM DTT and 200 mM Tris-HCl at pH 7.4 in a final volume 
of 60 μl. The mixture was incubated at 25 °C for 60 min. Then the reaction was quenched with 
60 μl 10% TFA. And this was followed by centrifugation to separate the precipitated proteins and 
the supernatant. The supernatant was analysed by high-performance liquid chromatography 
(Shimadzu) on a C18 column (HαSprite) monitored at 260-nm absorbance, using a linear gradient 
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from 0 to 40% buffer B over 20 min at a flow rate of 0.3 ml min−1 (buffer A: 50 mM ammonium 
acetate, pH 5.4; buffer B, 50% (v/v) methanol/water). 
UV-Vis spectroscopy of Dph1/Dph2 
Dph1/Dph2 (50 μM) was prepared anaerobically in 150 mM NaCl and 200 mM Tris-HCl at 
pH 7.4. The dithionite treated sample was allowed to incubate for 30 min after adding the 
reducing agent at a final concentration of 0.5 mM. The samples were sealed in a quartz cell 
(100 μl each) before being taken out of the anaerobic chamber. The UV-Vis spectra were 
obtained on a Cary 50 Bio UV-Vis spectrophotometer (Varian), scanning from 200 nm to 800 nm. 
The baseline was corrected with the buffer used to prepare the samples. 
Cloning, expression and purification of Dph3 and Dph4 
Yeast Dph3 and Dph4 was amplified from yeast genomic DNA, which was extracted from 
BY4741 using Pierce Yeast DNA Extraction Kit. The primers used for Dph3 were XS024 (5’- 
agtcagGATATCgatgtcaacatatgacgaaatc-3’) and JT008 (5’- 
AGTCAGCTCGAGTTAatggtgatgatggtggtgatggtgGGCAGCAGCGGCAATAGG-3’) and the 
primers used for Dph4 were XS023 (5’-agtcagGGATCCcatgtcattggtgaattcgttaa-3’) and XS003 
(5’-agtcagGTCGACttattgtccttcttgctcttcc-3’). Dph3 and Dph4 were inserted into pCDFduet 
vector respectively. The plasmid was used to transform BL21(DE3) pRARE2 strain. 
Cells were grown in 2 liters LB medium at 37°C and 200 rpm. It took 4-5 hours for the 
OD600	 to	 reach	 0.5 after inoculation with the overnight culture. Then the culturing 
temperature was changed to 15°C, and the protein expression was induced by 0.1 mM isopropyl-
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D-thiogalac-toside (IPTG). Cells were harvested after incubation at 15°C for 20 h. The protein 
was purified using a HisTrap column (GE Healthcare). Protein concentrations were determined 
by Bradford assay. 
UV-Vis spectroscopy of Dph3 
The UV-Vis spectra of Dph3 (87 μM) were obtained on a Cary 50 Bio UV-Vis spectrophotometer 
(Varian), scanning from 200 nm to 800 nm. The baseline was corrected with the buffer used to 
prepare the samples. The dithionite was added to the sample at a final concentration of 0.5 mM. 
The sample was then exposed to air to re-oxidize Dph3. 
Cloning, expression and purification of NorW 
NorW gene was amplified from the genomic DNA of E.coli. strain TOP10. The primers used 
were XS055 (5’-agtcagCATATGagtaacggcattgtgatcatc-3’) and XS056 (5’- 
agtcagCTCGAGctacatcggcaatgttttcaac-3’). NorW gene was inserted into pET28a vector. The 
plasmid was used to transform BL21(DE3) pRARE2 strain. Cells were grown in 2 liters 
LB medium at 37°C and 200 rpm. It took 4-5 hours for the OD600	 to	 reach	 0.5 after 
inoculation with the overnight culture. Then the culturing temperature was changed to 15°C, 
and the protein expression was induced by 0.1 mM isopropyl-D-thiogalac-toside (IPTG). Cells 
were harvested after incubation at 15°C for 20 h. The protein was purified using a HisTrap 
column (GE Healthcare). Protein concentrations were determined by Bradford assay. 
Reduction of Dph3 with NorW and NADH 
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The reaction was monitored on a Cary 50 Bio UV-Vis spectrophotometer (Varian), at the 
wavelength of 488 nm. Dph3 was used at the concentration of 87μM. NorW was added to a final 
concentration of 1 μM. NADH was used at a final concentration of 2mM.  
Expression and purification of yeast eEF-2.     
The plasmid p423 MET25-eEF-2 (hosted by strain HL610E) was used to transforme the S. 
cerevisiae cells with BY4741 background and the deletion of DPH2 gene (OpenBiosystems, 
Huntsville, AL). The expression and purification of eEF-2 was the same as previously reported. 
Anaerobic reconstitution of Dph1-4 activity 
The reaction mixture contained 4 μM Dph1, 4 μM Dph2, 20 μM Dph3, 20 μM Dph4, 2 μM eEF-2 
and 10 mM dithionite in the buffer of 150 mM NaCl, 1 mM DTT and 200 mM Tris-HCl at pH 7.4. 
The reaction mixture was assembled in the anaerobic chamber under strictly anaerobic conditions. 
The reaction vials were sealed before being taken out of the anaerobic chamber. 14C-SAM (2 μl, 
final concentration of 267 μM) was injected into each reaction vial to start the reaction. The 
reaction mixtures were vortexed briefly to mix and incubated at 30 °C for 60 min. The reaction 
was stopped by adding protein loading dye to the reaction mixture and subsequently heating at 
100 °C for 5 min, followed by 12% SDS–polyacrylamide gel electrophoresis. The dried gel was 
exposed to a PhosphorImaging screen (GE Healthcare) and the radioactivity was detected using a 
STORM 860 PhosphorImager (GE Healthcare). 
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CHAPTER 6 
SIRT5 IS AN NAD-DEPENDENT PROTEIN LYSINE DEMALONYLASE AND 
DESUCCINYLASE 
Abstract 
Sirtuins are NAD-dependent deacetylases that regulate important biological processes. Mammals 
have seven sirtuins, Sirt1-7. Four of them (Sirt4-7) have no detectable or very weak deacetylase 
activity. Here we found that Sirt5 is an efficient protein lysine desuccinylase and demalonylase in 
vitro. The preference for succinyl and malonyl groups was explained by the presence of an 
arginine residue (Arg105) and tyrosine residue (Tyr102) in the acyl pocket of Sirt5. Several 
mammalian proteins were identified to have succinyl or malonyl lysine modifications by mass 
spectrometry. Deletion of Sirt5 in mice appeared to increases the level of succinylation on 
carbamoyl phosphate synthase 1, a known target of Sirt5. Thus protein lysine succinylation may 
represent a posttranslational modification that can be reversed by Sirt5 in vivo.  
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Introduction 
Silent Information Regulator 2 (Sir2) proteins, or sirtuins, are a family of evolutionally conserved 
enzymes with nicotinamide adenine dinucleotide (NAD)-dependent deacetylase activity (Figure 
6.1)(1-3). Since the initial discovery of the deacetylase activity(4, 5), many important biological 
functions of sirtuins have been revealed(2, 3). Based on sequence similarity, sirtuins can be 
grouped into different classes(6). Mammals have seven sirtuins, Sirt1-7. Among them, only Class 
I sirtuins (Sirt1-3) have robust deacetylase activity. Sirt4-7 have either no detectable or very weak 
deacetylase activity(7-11).   
 
Figure 6.1 The sirtuins catalyzed NAD-dependent deacylation reaction (A) Deacetylation 
reaction and the resulting O-acetyl-ADP-ribose. (B) Mechanism of sirtuin-catalyzed NAD-
dependent deacetylation. Some of the oxygen atoms were colored differently to indicate where 
they come from. 
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Results and discussion 
To check whether the lack of robust deacetylase activity for Sirt4-7 is due to strict requirement 
for the peptide sequence, the activities of six human sirtuins (all except Sirt4, which could not be 
expressed in soluble forms in E. coli) were monitored using 16 different acetyl peptides (Table 
6.1). Under the experimental conditions used, Sirt1-3 and 5 showed deacetylase activity, but Sirt6 
and Sirt7 did not. All 16 peptides could be deacetylated by Sirt1-3, while only eight could be 
deacetylated slowly by Sirt5 (data not shown). A histone H3K9 acetyl peptide was one of the best 
substrates for Sirt1-3 and Sirt5. With this peptide, the kcat and Km of different sirtuins were 
determined (Table 6.2). The catalytic efficiency (kcat/Km) of Sirt5 was about 500-fold lower than 
that of Sirt1.
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Table 6.1 Acetyl peptides used to assay the deacetylase activity of sirtuins. 
Protein/lysine residue Peptide sequence 
Predicted mass 
(m/z) 
Observed mass 
(m/z) 
Histone H3 K9 (1-17) ARTKQTAR(AcK)STGGKAPR 928.6 [M+2H]2+ 928.5 [M+2H]2+ 
Histone H3 K9 (4-15) KQTAR(AcK) STGGKA 1274.7 [M+H]+ 1273.8 [M+H]+ 
Histone H3 K14 (6-22) TARKSTGG(AcK)APRKQLAT 907.0 [M+2H]2+ 906.7 [M+2H]2+ 
Histone H4 K5 (1-16) SGRG(AcK)GGKGLGKGGAK 728.9 [M+2H]2+ 728.8 [M+2H]2+ 
Histone H4 K8 (1-16) SGRGKGG(AcK)GLGKGGAK 728.9 [M+2H]2+ 728.8 [M+2H]2+ 
Histone H4 K12 (1-16) SGRGKGGKGLG(AcK)GGAK 728.9 [M+2H]2+ 728.6 [M+2H]2+ 
Histone H4 K16 (8-24) KGLGKGGA(AcK)RHRKVLRD 959.6 [M+2H]2+ 958.9 [M+2H]2+ 
Histone H4 K91 (80-99) TVTAMDVVYAL(AcK)RQGRTLYG 1142.6 [M+2H]2+ 1142.2 M+2H]2+ 
Histone H2A K5 (1-17) SGRG(AcK)QGGKARAKAKTR 900.0 [M+2H]2+ 899.3 [M+2H]2+ 
Histone H2A K13 (1-17) SGRGKQGGKARA(AcK)AKTR 900.0 [M+2H]2+ 899.8 [M+2H]2+ 
Histone H2B K5 (1-18) PEPA(AcK)SAPAPKKGSKKAV 917.1 [M+2H]2+ 916.7 [M+2H]2+ 
Histone H2B K12 (1-18) PEPAKSAPAPK(AcK)GSKKAV 917.1 [M+2H]2+ 916.8 [M+2H]2+ 
Histone H2B K15 (1-18) PEPAKSAPAPKKGS(AcK)KAV 917.1 [M+2H]2+ 916.4 [M+2H]2+ 
-tubulin K40 (32-48) PDGQMPSD(AcK)TIGGGDDS 859.9 [M+2H]2+ 859.4 [M+2H]2+ 
p53 K382 (374-389) GQSTSRHK(AcK)LMFKTEG 939.0 [M+2H]2+ 938.5 [M+2H]2+ 
Acetyl-CoA synthetase 2  
K642 (620-636) 
RLPKTRSG(AcK)VMRRLLRK 1069.2 [M+2H]2+ 1068.6 [M+2H]2+ 
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Table 6.2 The kinetic parameters of four human sirtuins on H3 K9 acetyl peptide 
Sirtuins kcat (s-1) Km for acetyl peptide (M) kcat/Km (s-1M-1) 
Sirt1 0.039 ± 0.001 38 ± 4 1.0 x 103 
Sirt2 0.030 ± 0.001 190 ± 14 1.6 x 102 
Sirt3 0.012 ± 0.001 50 ± 9 2.4 x 102 
Sirt5 ND* ND (>750)* 2.0 
* The kcat and Km values for Sirt5 could not be determined because the V versus [S] plot was 
linear (Km was greater than the highest substrate concentration tested). Thus only kcat/Km value 
can be obtained.  
The kcat and Km values were obtained by curve-fitting the Vinitial/[E] versus [S] plot using 
KaleidaGraph. 
To understand why the deacetylase activity of Sirt5 is weak, a crystal structure of Sirt5 in 
complex with a thioacetyl peptide was obtained (the corresponding acetyl peptide could not be 
crystallized with Sirt5). A buffer molecule, CHES (N-cyclohexyl-2-aminoethanesulfonic acid), 
was also bound to Sirt5 (Figure 6.2A and 6.3A). The interactions between the thioacetyl peptide 
and Sirt5 involved mostly backbone hydrogen bonding (Figure 6.3B), similar to what was 
observed for Thermotoga maritime Sir2 (Sir2Tm), a sirtuin with robust deacetylase activity(12). 
Thus, the selectivity for peptide sequences is unlikely to be the major reason for the lack of robust 
deacetylase activity for Sirt5. 
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Figure 6.2 The structure of Sirt5 revealed an unusual acyl pocket. (A) The acyl pocket of Sirt5 
was partially occupied by the sulfate from the CHES molecule via interactions with Arg105 and 
Tyr102. The sulfur was 4.2 Å away from the thioacetyl group. (B) Alignment of Sirt5-thioacetyl 
peptide structure (grey) and Sir2Tm-acetyl peptide structure (PDB 2h4f, magenta). 
 
Figure 6.3 (A) Overall structure of Sirt5 in complex with an H3K9 thioacetyl peptide. The 
thioacetyl lysine side chain (green) and the CHES molecule (cyan) are shown in stick (cyan). (B) 
H-bonding interactions (dashed yellow lines) between thioacetyl peptide (green) and Sirt5 (light 
grey).   
 
When the Sirt5 structure was superimposed with the structure of Sir2Tm in complex with an 
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acetyl peptide and NAD (PDB 2h4f) (Figure 6.2B)(13), the positions of the thioacetyl lysine in 
Sirt5 and the acetyl lysine in Sir2Tm were almost identical in the superimposed structures. The 
acetyl group in the Sir2Tm structure was surrounded by three hydrophobic residues, Phe48, 
Ile100, and Ile159. In contrast, the corresponding pocket in Sirt5 was larger and bound by CHES. 
The sulfate group of CHES interacted with Tyr102 and Arg105 of Sirt5 and was ~4 Å away from 
the thioacetyl group (Figure 6.2A). In the reported Sirt5 structure with HEPES bound(9), the 
sulfate from HEPES also interacted with Arg105 and Tyr102. 
Based on the above structural analysis, we reasoned that if the acetyl group was replaced with an 
acyl group bearing a negatively-charged carboxylate, the acyl peptide should bind Sirt5 better 
than the acetyl peptide and thus may be a better substrate for Sirt5 (Figure 6.4). In cells, the most 
common acyl-CoA molecules with a carboxylate group are malonyl-CoA and succinyl-CoA(14). 
Malonyl-CoA, made from acetyl-CoA by acetyl-CoA carboxylase in the cytosol and the 
mitochondria, is a precursor for fatty acid biosynthesis(15, 16). Succinyl-CoA is an intermediate 
in the Krebs cycle in the mitochondria. Since acetyl-CoA is used to modify proteins in cells, it is 
possible that malonyl- and succinyl-CoA could also be used to modify proteins. Thus, H3K9 
malonyl and succinyl peptides were synthesized and tested for hydrolysis by Sirt5. 
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Figure 6.4  The rationale for predicting that malonyl/succinyl peptides could be better substrates 
for Sirt5. 
Liquid chromatography–mass spectrometry (LC-MS) was used to monitor the reactions.  Sirt1, 2, 
and 3 catalyzed the hydrolysis of the acetyl peptide, but not the malonyl or succinyl peptide 
(Figure 6.5A-C and 6.6-6.9).  In contrast, with Sirt5, little hydrolysis of the acetyl peptide was 
observed, but the malonyl and succinyl peptides were hydrolyzed significantly (Figure 6.5D-F, 
Fig. 6.6-6.8,6.10). The deacylated peptides have identical masses to the synthetic unmodified 
peptide (Figure 6.6 and 6.9). Sirt6 and Sirt7 had no detectable activity on the acyl peptides under 
the conditions tested (Figure 6.11). Thus, Sirt5 is a desuccinylase and demalonylase.  
 119 
 
 
Figure 6.5  Sirt5 catalyzed the hydrolysis of malonyl and succinyl lysine. The enzymatic 
reactions were analyzed by LC-MS. Pink traces showed the ion intensities (10x magnified) for 
the masses of the acyl peptides (acetyl, m/z 1274.0; malonyl, m/z 1318.0; succinyl, m/z 1332.0) 
and blue traces showed the ion intensities (10x magnified) for the mass of the deacylated peptide 
(m/z 1232.0). Black traces showed the ion intensity for all masses from 100-2000 (total ion 
counts or TIC). With Sirt1, hydrolysis was observed for the acetyl peptide (A), but not malonyl 
(B) or succinyl (C) peptide. With Sirt5, hydrolysis of the acetyl peptide was barely detectable (D) 
while hydrolysis of the malonyl (E) and succinyl (F) peptides were obvious. 
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Figure 6.6 Sirt1 and Sirt5 catalyzed-hydrolysis of different acyl peptides monitored using LC-
MS. For each reaction, the LC trace, MS trace, deacylated peptide mass spectra and acyl peptide 
mass spectra are shown. LC traces detect the UV-Vis absorption at 215 nm of compounds coming 
off the column, and MS traces detect the masses of the compounds coming off the column. In the 
MS trace, pink traces show the ion intensities (10x magnified) for the masses of the acyl peptides 
(acetyl, m/z 1274.0; malonyl, m/z 1318.0; succinyl, m/z 1332.0) and blue traces show the ion 
intensities (10x magnified) for the mass of the deacylated peptide (m/z 1232.0). Black traces 
show the ion intensity for all masses from 100-2000 (total ion counts or TIC). With Sirt1, the 
deacetylated product was detected when H3K9 acetyl peptide (A) was used as the substrate. With 
Sirt5, the demalonylated (B) and desuccinylated (C) products were detected.  
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Figure 6.7 Sirt1 and Sirt5-catalyzed deacetylation, demalonylation and desuccinylation of H3 K9 
peptides were examined by HPLC (monitored at 215 nm).  In Figure 6.6, LC-MS was used to 
monitor the reactions. However, in the LC traces, the acyl peptide and deacylated peptide peaks 
overlapped with other peaks. Here, a longer HPLC column was used to better separate the acyl 
peptide and deacylated peptide. The results further confirmed that Sirt1 had better deacetylase 
activity, while Sirt5 had better demalonylase and desuccinylase activity. 
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Figure 6.8 In the absence of Sirt5 or NAD, malonyl and succinyl peptides could not be 
hydrolyzed. Shown here are the MS traces from the LC-MS analyses for the reactions. Pink traces 
show the ion intensities (10x magnified) for the masses of the acyl peptides (acetyl peptide, m/z 
1274.0; malonyl peptide, m/z 1318.0; succinyl peptide, m/z 1332.0) and blue traces show the ion 
intensities (10x magnified) for the mass of the deacylated peptide (m/z 1232.0). Black traces 
show the intensity for total ion counts (TIC). There was no deacylated peptide generated without 
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sirtuin (A, B, C) or NAD (D and E). 
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Figure 6.9 LC-MS of synthetic unmodified H3K9 peptide. The LC trace, MS trace, and mass 
spectra are shown from top to bottom. LC traces detect the UV-Vis absorption at 215 nm of 
compounds coming off the column, and MS traces detect the masses of the compounds coming 
off the column. Pink traces show the ion intensities (10x magnified) for the masses of the 
unmodified peptide (m/z 1232.0). Black traces show the ion intensity for all masses from 100-
2000 (total ion counts or TIC). The demalonylated and desuccinylated peptides (Fig. S4) had 
identical masses to the synthetic unmodified H3K9 peptide. 
 126 
 
15.0 16.0 17.0 18.0 19.0 min
0
25000
uV
15.0 16.0 17.0 18.0 19.0 min
0
250000
uV
NAD + H3K9 WW malonyl without Sirt5
NAD + H3K9 WW malonyl with Sirt5
NAD + H3K9 WW malonyl without Sirt5
NAD + H3K9 WW malonyl with Sirt5
Detector 280 nm
Detector 215 nm
demalonylated peptide
malonyl peptide
demalonylated peptide
malonyl peptide
 
 
Figure 6.10 HPLC traces for the demalonylation reactions with H3K9 WW peptide were 
monitored at 280 nm and 215 nm.  The pink traces are controls showing the peptides without 
Sirt5.  The black traces are the reactions with Sirt5.  The new peak at 18.3 min is the 
demalonylated product. 
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Figure 6.11 Sirt2, Sirt3, Sirt6, and Sirt7 did not catalyze the hydrolysis of malonyl and succinyl 
lysine. Shown here are the MS traces from the LC-MS analyses of the reactions. Pink traces show 
the ion intensities (10x magnified) for the masses of the acyl peptides (acetyl peptide, m/z 1274.0; 
malonyl peptide, m/z 1318.0; succinyl peptide, m/z 1332.0) and blue traces show the ion 
intensities (10x magnified) for the mass of the deacylated peptide (m/z 1232.0). Black traces 
show the intensity for total ion counts (TIC). Sirt2 and Sirt3 only displayed deacetylation activity, 
while no activity was detected for Sirt6 and Sirt7. 
The kcat and Km values for Sirt5-catalyzed deacetylation, demalonylation, and desuccinylation 
were determined (Table 6.3, Figure 6.12) with three different peptide sequences (Table 6.4). With 
all three peptide sequences, the catalytic efficiencies for demalonylation and desuccinylation were 
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much (29 to >1000 fold) higher than that for deacetylation (Table 6.3).  
Table 6.3 The kinetic parameters of Sirt5 on acetyl, malonyl, and succinyl peptides with different 
sequences. 
Peptide  kcat (s-1) 
Km for peptide 
(M) 
kcat/Km (s-
1M-1) 
H3 K9  
(4-13+WW*) 
 
deacetylation ND ND (>750) 7.8 
demalonylation 0.037 ± 0.003 6.1 ± 2.8 6.1 × 103 
desuccinylation 0.025 ± 0.002 5.8 ± 2.7 4.3 × 103 
GDH K503 
(498-
509+WW*) 
 
deacetylation ND ND (>750) <2** 
demalonylation 0.014 ± 0.001 8.7 ± 1.3 1.6 × 103 
desuccinylation 0.028 ± 0.002 14 ± 4 2.0 × 103 
ACS2 K628  
(623-
632+WW*) 
 
deacetylation ND ND (>750) 18 
demalonylation 0.079 ± 0.008 150 ± 40 5.2 × 102 
desuccinylation 0.268 ± 0.051 450 ± 150 6.0 × 102 
* Two tryptophan residues were added at the C-terminal of the peptide to facilitate the detection 
by UV-Vis absorption during the HPLC assay. 
** No activity. The value was estimated based on the detection limit. 
ND: cannot be determined either because no activity was observed or because V versus [S] was 
linear (even the highest [S] of 750 M used was much smaller than the Km). 
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Table 6.4 Acetyl, thioacetyl, malonyl, and succinyl peptides used for Sirt5 crystallization and 
kinetics studies. 
Protein/lysine residue Peptide sequence 
Predicted mass 
 (m/z) 
Observed mass 
[M+H]+ (m/z) 
Histone H3 K9 (4-15) KQTAR(TacK)STGGKA 1290.7 [M+H]+ 1290.0 [M+H]+ 
Histone H3 K9 (4-15) KQTAR(MaK)STGGKA 1318.7 [M+H]+ 1317.7 [M+H]+ 
Histone H3 K9 (4-15) KQTAR(SuK)STGGKA 1332.7 [M+H]+ 1331.3 [M+H]+ 
Histone H3 K9 (4-13)WW KQTAR(AcK)STGGWW 724.4 [M+2H]2+ 724.7 [M+2H]2+ 
Histone H3 K9 (4-13)WW KQTAR(MaK)STGGWW 746.4 [M+2H]2+ 746.7 [M+2H]2+ 
Histone H3 K9 (4-13)WW KQTAR(SuK)STGGWW 753.4 [M+2H]2+ 753.7 [M+2H]2+ 
GDH K503 (498-509)WW SGASE(AcK)DIVHSGWW 800.9 [M+2H]2+ 801.2 [M+2H]2+ 
GDH K503 (498-509)WW SGASE(MaK)DIVHSGWW 822.9 [M+2H]2+ 823.1 [M+2H]2+ 
GDH K503 (498-509)WW SGASE(SuK)DIVHSGWW 829.9 [M+2H]2+ 830.2 [M+2H]2+ 
ACS2 K628 (623-632)WW KTRSG(AcK)VMRRWW 816.9 [M+2H]2+ 817.1 [M+2H]2+ 
ACS2 K628 (623-632)WW KTRSG(MaK)VMRRWW 838.9 [M+2H]2+ 839.1 [M+2H]2+ 
ACS2 K628 (623-632)WW KTRSG(SuK)VMRRWW 845.9 [M+2H]2+ 846.4 [M+2H]2+ 
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Figure 6.12 Time courses and sample HPLC traces from kinetic studies for Sirt5-catalyzed 
deacylation reactions. (A) Time course of Sirt5-catalyzed desuccinylation reaction using the 
H3K9 WW succinyl peptide. The desuccinylated peptide increased over time. The reaction was 
monitored at 280 nm.  Most substrates were converted to products after 10 min. (B) Time course 
of Sirt5-catalyzed deacetylation reaction using the H3K9 WW acetyl peptide. The deacetylated 
peptide increased over time. The reaction was monitored at 280 nm. A very small percentage of 
substrate was converted to product even after 180 min. (C) Sample HPLC traces from Sirt5 
kinetics studies. 
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A crystal structure of Sirt5 in complex with a succinyl peptide and NAD was obtained. The 
structure (Figure 6.13) showed that the carboxylate from succinyl interacted with Tyr102 and 
Arg105, consistent with what was predicted based on the structure of Sirt5 with CHES bound 
(Figure 6.4). Changing Arg105 to Met or Tyr102 to Phe significantly increased the Km for 
desuccinylation (Table 6.5). Thus, Tyr102 and Arg105 were important for binding succinyl and 
malonyl groups. 
 
Figure 6.13 Sirt5-succinyl peptide-NAD ternary structure showing that the succinyl group 
interacted with Tyr102 and Arg105. 
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Table 6.5 The kinetic parameters of mutant Sirt5 on H3K9 acetyl and succinyl peptides 
  kcat (s-1) Km for peptide (M) kcat/Km (s-1M-1) 
Sirt5 
deacetylation ND* ND (> 750)* 2 
desuccinylation 0.029 ± 0.002 41 ± 11 710 
Sirt5 H158Y 
deacetylation no activity observed no activity observed - 
desuccinylation ND* ND (> 750)* 75 
Sirt5 Y102F 
deacetylation ND* ND (> 750)* 2 
desuccinylation ND* ND (> 750)* 397 
Sirt5 R105M 
deacetylation ND* ND (> 750)* 0.5 
desuccinylation ND* ND (> 750)* 0.9 
* The kcat and Km values cannot be determined because the V versus [S] plot is linear (Km is much 
greater than the highest substrate concentration tested, 750 M). Thus only kcat/Km value can be 
obtained. 
We next determined whether lysine malonylation or succinylation exists in vivo. Lysine 
succinylation was reported to occur on E. coli homoserine trans-succinylase(17), but lysine 
malonylation has not been reported. We thought that detecting Sirt5-catalyzed formation of O-
Ma-ADPR or O-Su-ADPR using 32P-NAD could be a sensitive assay to detect the presence of 
malonyl or succinyl lysine. H3K9 acetyl, malonyl, and succinyl peptides were incubated with 
Sirt5 or Sirt1 in the presence of 32P-NAD. The small molecule products were then separated by 
thin-layer chromatograph (TLC) and detected by autoradiography. With malonyl and succinyl 
peptides, Sirt5 consumed all the NAD molecules and new spots that corresponded to O-Ma-
ADPR and O-Su-ADPR appeared (Figure 6.14). With the acetyl peptide, essentially no NAD was 
consumed by Sirt5 (Figure 6.14). Incubation of the acetyl peptide or calf thymus histones with 
Sirt1 produced O-Ac-ADPR (Figure 6.14). The O-Su-ADPR spot was separated from the O-Ac-
ADPR and O-Ma-ADPR spots. Thus, Sirt5-catalyzed formation of O-Su-ADPR from the 
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hydrolysis of succinyl peptides could be detected using 32P-NAD. 
 
Figure 6.14 Succinyl lysine was detected in bovine liver mitochondria. Sirt5-catalyzed hydrolysis 
of malonyl and succinyl peptides could be detected using 32P-NAD, which formed 32P-labeled O-
Ma-ADPR (lane 2) and O-Su-ADPR (lane 3). No reaction occurred with acetyl peptide (lane 1). 
The formation of O-Ac-ADPR catalyzed by Sirt1 was detected (lanes 4 and 8). O-Su-ADPR was 
formed when bovine liver mitochondria peptides were incubated with Sirt5 (lane 9), but not with 
Sirt1 (lane 10). The control with BSA peptides and Sirt5 did not generate O-Su-ADPR (lane 12). 
CD38-catalzyed hydrolysis of NAD was used to generate the standard 32P-ADPR spot (lane 13). 
The 32P-NAD assay was then used to detect whether succinyl lysine was present in bovine liver 
mitochondrial proteins because Sirt5 is localized in mitochondria(7). When bovine liver 
mitochondrial peptides were treated with Sirt5 and 32P-NAD, the formation of O-Su-ADPR was 
detected (Figure 6.14), suggesting that bovine liver mitochondrial proteins contained succinyl 
lysine. Control reactions with Sirt1, without sirtuins, or with BSA peptides did not produce O-Su-
ADPR or O-Ac-ADPR (Figure 6.14).  
LC-MS/MS identified succinyl lysine from three commercial mitochondrial enzymes purified 
 134 
 
from animal tissues: glutamate dehydrogenase (GDH), malate dehydrogenase, and citrate 
synthase (Table 6.6 and 6.7). Thus, lysine succinylation occurs on mammalian mitochondrial 
proteins. Also, LC-MS/MS of commercial mitochondrial enzymes identified three and two 
malonyl lysine residues on GDH (Table 6.6) and malate dehydrogenase (Table 6.7), respectively. 
The tandem mass spectra confirmed the identities of the these peptides and modification sites. 
(see the online supplementary information 
http://www.sciencemag.org/content/suppl/2011/11/10/334.6057.806.DC1/Du-SOM.pdf). Thus, 
protein lysine malonylation exists in mammalian cells.  
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Table 6.6 Acetyl, malonyl, and succinyl GDH peptides identified by LC-MS/MS. 
 Peptide sequence and modification 
1 77-GASIVEDK(acetyl)LVEDLK-90 
2 77-GASIVEDK(succinyl)LVEDLK-90 
3 85-LVEDLK(acetyl)TR-92 
4 108-IIK(acetyl)PCNHVLSLSFPIR-123 
5 108-IIK(succinyl)PCNHVLSLSFPIR-123 
6 152-YSTDVSVDEVK(acetyl)ALASLMTYK-171 
7 152-YSTDVSVDEVK(acetyl)ALASLM(ox)TYK-171 
8 152-YSTDVSVDEVK(succinyl)ALASLMTYK-171 
9 172-CAVVDVPFGGAK(acetyl)AGVK-187 
10 188-INPK(acetyl)NYTDNELEK-200 
11 353-LQHGTILGFPK(acetyl)AK-363 
12 353-LQHGTILGFPK(succinyl)AK-363 
13 364-AK(acetyl)IYEGSILEVDCDILIPAASEK-386 
14 366-IYEGSILEVDCDILIPAASEK(acetyl)QLTK-390 
15 398-AK(acetyl)IIAEGANGPTTPEADK-415 
16 398-AK(acetyl)IIAEGANGPTTPEADKIFLER-420 
17 400- IIAEGANGPTTPEADK(acetyl)IFLER-420 
18 400- IIAEGANGPTTPEADK(succinyl)IFLER-420 
19 454-LTFK(acetyl)YER-460 
20 454-LTFK(malonyl)YER-460 
21 454-LTFK(succinyl)YER-460 
22 478-FGK(acetyl)HGGTIPIVPTAEFQDR-496 
23 497-ISGASEK(acetyl)DIVHSGLAYTMER-516 
24 497-ISGASEK(malonyl)DIVHSGLAYTMER-516 
25 497-ISGASEK(succinyl)DIVHSGLAYTMER-516 
26 497-ISGASEK(succinyl)DIVHSGLAYTM(ox)ER-516 
27 524-TAMK(acetyl)YNLGLDLR-535 
28 524-TAM(ox)K(acetyl)YNLGLDLR-535 
29 524-TAMK(malonyl)YNLGLDLR-535 
30 524-TAMK(succinyl)YNLGLDLR-535 
31 524-TAM(ox)K(succinyl)YNLGLDLR-535 
32 536-TAAYVNAIEK(acetyl)VFR-548 
33 536-TAAYVNAIEK(succinyl)VFR-548 
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Table 6.7 Acetyl, malonyl, and succinyl peptides identified on other metabolic enzymes 
Proteins  Modified peptides 
Malate dehydrogenase, mitochondrial 
1 177-ANAFVAELK(acetyl)GLDPAR-191 
2 230-IQEAGTEVVK(succinyl)AK-241 
3 230-IQEAGTEVVK(malonyl)AK-241 
4 297-KGIEK(succinyl)NLGIGK-307 
5 298-GIEK(succinyl)NLGIGK-307 
6 302-NLGIGK(acetyl)ISPFEEK-314 
7 308-ISPFEEK(acetyl)M(ox)IAEAIPELK-324 
8 325-ASIK(acetyl)KGEEFVK-335 
9 325-ASIKK(malonyl)GEEFVK-335 
10 325-ASIK(succinyl)KGEEFVK-335 
Citrate synthase, mitochondrial 
1 74-GMK(acetyl)GLVYETSVLDPDEGIR-92 
2 74-GMK(succinyl)GLVYETSVLDPDEGIR-92 
3 74-GMK(succinyl)GLVYETSVLDPDEGIRFR-94 
 
Sirt5 is known to regulate the activity of carbamoyl phosphate synthase 1 (CPS1)(18). We 
therefore sought to test whether CPS1 was a desuccinylation target of Sirt5. Trypsin-digested 
CPS1 peptides from bovine liver mitochondria contained succinyl lysine (Figure 6.15). To 
confirm that Sirt5’s desuccinylase functions in vivo, a Sirt5 knockout (KO) mouse strain was 
generated using standard technology. Consistent with earlier reports(18), CPS1 activity was 15% 
higher in Sirt5 wt than in Sirt5 KO mice. Using MS, we identified three lysine residues of CPS1 
that are both acetylated and succinylated: Lys44, Lys287, and Lys1291. For Lys44 and Lys287, 
the levels of acetylation and succinylation did not change in Sirt5 KO mice. For Lys1291, 
succinylation level increased 16 to >100-fold in Sirt5 KO mice compared with the level in wt 
mice (Figure 6.16). In contrast, acetylation levels of Lys1291 did not change in Sirt5 KO 
compared with wt (Figure 6.16).  Thus, Sirt5 functions as a desuccinylase in vivo. 
 137 
 
1   2   3   4   5   6   7   8   9
Hst2 - +  - - - - - - +
Sirt5 - - - +  - +  - +  -
H3K9Ac +  +  - - - - - - -
H3K9Ma - - +  +  - - - - -
H3K9Su - - - - +  +  - - -
Trypsin digested CPS1  - - - - - - +  +  +
1   2   3   4   5   6   7   8   9
Hst2 - +  - - - - - - +
Sirt5 - - - +  - +  - +  -
H3K9Ac +  +  - - - - - - -
H3K9Ma - - +  +  - - - - -
H3K9Su - - - - +  +  - - -
Trypsin digested GDH - - - - - - +  +  +
1   2   3   4   5   6   7   8   9
Hst2 - +  - - - - - - +
Sirt5 - - - +  - +  - +  -
H3K9Ac +  +  - - - - - - -
H3K9Ma - - +  +  - - - - -
H3K9Su - - - - +  +  - - -
Trypsin digested histone   - - - - - - +  +  +
A
B
C
 
Figure 6.15 Succinyl lysine modification could be detected in CPS1 and GDH peptides.  
Different proteins were digested by trypsin and then incubated with 32P-NAD and either Sirt5 or 
Hst2.  For each panel, lane 1, 3 and 5 were negative controls without sirtuins.  Lane 2, 4 and 6 
were positive controls showing the positions of O-acetyl-, O-malonyl- and O-succinyl-ADP 
ribose on the TLC plate, respectively.  Lane 7 was trypsin digested peptides without any sirtuin.  
Lane 8 and 9 were trypsin digested peptides treated with Sirt5 and Hst2 respectively.  Lane 8 in 
all 3 samples showed the formation of O-Su-ADPR while lane 9 showed the formation of O-Ac-
ADPR. The results showed that both CPS1 and GDH contain succinyl lysine modification. In 
contrast, very little succinyl lysine modification was detected on histone peptides. 
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Figure 6.16 Relative quantitation analysis was achieved by extracted ion chromatograms (XICs) 
for peak areas of CPS1 K1291 acetyl peptides from Sirt5 KO (A) and wt mice (B); of CPS1 
K1291 succinyl peptides from Sirt5 KO (C) and wt mice (D), and of a reference peptide from 
Sirt5 KO (E) and wt mice (F). 
Here we have demonstrated that Sirt5 is an NAD-dependent demalonylase and desuccinylase. 
The demalonylase or desuccinylase activity is much higher than its deacetylase activity. The 
preference for negatively charged acyl groups can be explained by the presence of Tyr102 and 
Arg105 in the active site of Sirt5, which are conserved in most Class III sirtuins (Figure 6.17)(6). 
Presumably all Class III sirtuins with the conserved Arg and Tyr should have NAD-dependent 
desuccinylase and/or demalonylase activity.  
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Figure 6.17 Tyr and Arg residues are conserved in most Class III sirtuins. The conservation of 
specific sequences motifs within the 14 Class III sirtuins were aligned and the conserved Tyr102 
and Arg105 (Sirt5 numbering) residues are shaded. 
We showed that lysine malonylation and succinylation occur on several mammalian proteins. 
Protein lysine succinylation has been observed recently in bacteria(19). Protein lysine 
malonylation has not been reported previously. 
Acetylation occurs on numerous metabolic enzymes and regulates their activities in mammals and 
bacteria(20, 21). Given that succinyl-CoA and malonyl-CoA are common metabolites like acetyl-
CoA(14), and all the succinylated and malonylated proteins we found are metabolic enzymes, it is 
likely that protein lysine succinylation and malonylation function similarly to acetylation and 
regulate metabolism(20, 21).  
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Methods 
Reagents and Instrumentation.  
Reagents were obtained from Aldrich or Acros in the highest purity available and used as 
supplied. 1H NMR, 13C NMR and 2D NMR were performed on INOVA 500 spectrometer. NMR 
data was analyzed by MestReNova (version 5.2.5). LCMS was carried out on a SHIMADZU LC-
MS-QP8000α with a Sprite TARGA C18 column (40  2.1 mm, 5 m, Higgins Analytical, Inc., 
Mountain View, CA) monitoring at 215 and 260 nm. Solvents used in LC-MS were water with 
0.1% formic acid and acetonitrile with 0.1% formic acid.  
Synthesis of Fmoc-Lys(tBu-malonyl)-OH and Fmoc-Lys(tBu-succinyl)-OH.  
Mono-tbutyl-malonate (480 mg, 3.0 mmol) or mono-tbutyl-succinate (522.0 mg, 3 mmol) in 
anhydrous N,-N’-dimethylformamide (DMF, 2.0 mL) was added N-hydroxysuccinimide (334 mg, 
2.9 mmol) with stirring at room temperature. Then N,N’-dicyclohexylcarbodiimide (598 mg, 2.9 
mmol) in anhydrous DMF (3.0 mL) was added to the reaction. After stirring for 2 h, the reaction 
mixture was filtered. The filtrate was added to a solution of Fmoc-Lys-OH (736 mg, 2.0 mmol) 
with N, N-diisopropylethylamine (DIEA, 1.0 mL, 5.8 mmol) in anhydrous DMF (2.0 mL) at 
room temperature. The resulting reaction mixture was stirred for another 30 min. Then the 
reaction mixture was added 10 mL water and 6 mL 1 M HCl to adjust pH to 2~3. The mixture 
was extracted three times by 100 mL ethyl acetate and washed twice with 50 mL brine. The 
organic layer was dried with anhydrous sodium sulfate. After removal of the solvents in vacuo, 
the residue was purified by silica gel column using 10:1 CH2Cl2:CH3OH to give the desired 
product in about 90% yield. 
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Fmoc-Lys(tBu-Malonyl)-OH. 1H NMR (500 MHz, DMSO-d6):  8.01 (t, 1H, J = 5.5 Hz), 7.89 (d, 
2H, J = 7.0 Hz), 7.73 (dd, 2H, J = 2.0, 7.0 Hz), 7.46 (d, 1H, J = 7.0 Hz), 7.41 (t, 2H, J = 7.5 Hz), 
7.33 (t, 2H, J = 7.8 Hz), 4.27 (m, 2H), 4.23 (m, 1H), 3.87 (dt, 1H, J = 4.5, 8.5 Hz), 3.07 (s, 2H), 
3.03 (m, 2H), 1.65 (m, 2H), 1.39 (m, 2H), 1.38 (s, 9H), 1.33 (m, 2H). 13C NMR (125 MHz, 
DMSO-d6):  174.26, 167.29, 165.24, 156.08, 143.91, 143.84, 140.75, 140.73, 127.66, 127.11, 
125.33, 120.15, 120.14, 80.40, 80.39, 65.57, 54.10, 46.70, 43.74, 38.51, 30.74, 28.65, 27.70, 
23.02. LC-MS (ESI) calcd. for C28H35N2O7 [M+H+] 511.3, obsd. 510.8. 
Fmoc-Lys(tBu-Succinyl)-OH. 1H NMR (500 MHz, CD3OD):  7.75 (d, 2H, J = 8.0 Hz), 7.61 (dd, 
2H, J = 4.5, 7.5 Hz), 7.35 (t, 2H, J = 7.3 Hz), 7.26 (t, 2H, J = 7.3 Hz), 4.30 (m, 2H), 4.15 (t, 1H, J 
= 7.0 Hz), 4.04 (dd, 1H, J = 4.5, 8.0 Hz), 3.14 (t, 2H, J = 7.0 Hz), 2.49 (t, 2H, J = 7.0 Hz), 2.38 (t, 
2H, J = 7.3 Hz), 1.75 (m, 2H), 1.49 (m, 2H), 1.40 (s, 9H), 1.37 (m, 2H). 13C NMR (125 MHz, 
CD3OD):  180.22, 174.46, 173.72, 158.64, 145.49, 145.28, 142.69, 142.68, 128.91, 128.29, 
126.38, 126.35, 121.07, 81.81, 67.97, 57.11, 48.54, 40.37, 33.23, 31.93, 31.87, 30.17, 28.48, 
24.32. LC-MS (ESI) calcd. for C29H37N2O7 [M+H+] 525.3, obsd. 524.8. 
Cloning, expression and purification of human Sirtuins 
Human Sirt1, 2, 3, 5, and 6 were expressed as previously described(22). Human Sirt7 coding 
sequence was PCR-amplified using primers JT072 (5’-
AGTCAGGAATTCATGGCAGCCGGGGGTCT-3’) and JT073 (5’-
AGTCAGCTCGAGTTACGTCACTTTCTTCCTTTTT-3’). Amplified product was digested with 
EcoRI and XhoI. The digested PCR product was purified and ligated into the similarly digested 
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expression vector pET28a. C-terminal Flag-tagged Sirt5 (Flag-Sirt5) and truncated Sirt5(34-302) 
were cloned using TOPO and Gateway cloning technology (Invitrogen Corp., Carlsbad, CA) into 
pDEST-F1 for expression. Sirt7, Flag-Sirt5 and Sirt5(34-302) were expressed in E. coli and 
purified as described.  After purification, Flag-Sirt5 and Sirt5(34-302) were digested by TEV at 
room temperature for 2 h and purified by HisTrapTM HP Column (GE Healthcare, Piscataway, 
NJ) and gel filtration on a HiLoad 26/60 Superdex 75 prep grade column (GE Healthcare, 
Piscataway, NJ). Protein concentrations were determined by Bradford reagent. 
Sirt5 X-ray diffraction data collection and structural refinement.  
Sirt5-H3K9 thioacetyl peptide and Sirt5-H3K9 succinyl peptide were prepared at a 1:20 
protein:peptide molar ratio and incubated for 30~60 min on ice. Crystals were grown by the 
method of hanging drop vapor diffusion. Sirt5-H3K9 succinyl peptide co-crystals were soaked in 
10 mM NAD for 10~120 min before data collection. All the X-ray diffraction data were collected 
at CHESS (Cornell High Energy Synchrotron Source) A1 or F1 station. The data were processed 
using the programs HKL2000. The two structures of Sirt5 complexes were solved by molecular 
replacement using the program Molrep from the CCP4 suite of programs. The Sirt5-ADPR 
structure (PDB code: 2B4Y) was served as the searching template. Refinement and model 
building were performed with REFMAC5 and COOT from CCP4.  
Synthesis of acetyl, thioacetyl, malonyl, and succinyl peptides 
Acetyl, thioacetyl, malonyl and succinyl peptides were synthesized on Wang resin using standard 
Fmoc/tBu chemistry O-benzotriazol-N,N,N’,N’-tetramethyluronium hexafluorophosphate/1-
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hydroxybenzotriazol (HBTU/HOBt) protocol(22). Modified lysine was incorporated using Fmoc-
Lys(acetyl)-OH, Fmoc-Lys(thioacetyl)-OH, Fmoc-Lys(tBu-malonyl)-OH and Fmoc-Lys(tBu-
succinyl)-OH. Cleavage from the resin and removal of all protecting groups were done by 
incubating the resin with trifluoroacetic acid (TFA) containing phenol (5%), thioanisole (5%), 
ethanedithiol (2.5%), and water (5%) for 2 h. The crude peptides were purified by reverse phase 
HPLC on BECKMAN COULTER System Gold 125P solvent module & 168 Detector with a 
TARGA C18 column (250  20 mm, 10 m, Higgins Analytical, Inc., Mountain View, CA) 
monitoring at 215 nm. Mobile phases used were 0.1% aqueous TFA (solvent A) and 0.1% TFA in 
acetonitrile (solvent B). Peptides were eluted with a flow rate of 10 mL/min with the following 
gradient: 0% solvent B for 5 min, then 0 % to 25% solvent B over 25 min. The identity and purity 
of the peptides were verified by LC-MS. Table 6.1 and 6.4 listed the synthetic peptides. 
Deacetylation, demalonylation, and desuccinylation activity assay and determination of kcat 
and Km. 
The deacylase activity of human Sirt1, Sirt2, Sirt3, Sirt5, Sirt6 and Sirt7 were measured by 
detecting the deacylated peptide from the acyl peptides (Table 6.1 and 6.4) using LC-MS. 
Purified sirtuin was incubated with 0.3 mM acyl peptides, 1.0 mM NAD in 20 mM Tris-HCl 
buffer (pH 7.5) containing 1 mM DTT in 60 L reactions for 2 h at 37°C. The reactions were 
stopped with 60 L 10% TFA and analyzed by LC-MS. 
For determination of kcat and Km, human Sirt1, Sirt2, Sirt3 and Sirt5 were measured by detecting 
the deacylated peptide from H3K9 acyl peptides using HPLC. Purified sirtuin was incubated with 
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1.0 mM of NAD in 20 mM Tris-HCl buffer (pH 7.5) containing acyl peptides (0–750 M) and 
1 mM DTT in 60 L reactions at 37°C. The reactions were stopped with 100 mM HCl and 
160 mM acetic acid, analyzed by HPLC with a reverse phase C18 column (250 × 4.6 mm, 90 A, 
10 m, GraceVydac, Southborough, MA), with a linear gradient of 0% to 20% B for 10 min (1 
mL/min). Product quantification was based on the area of absorption monitored at 215 nm, 
assuming hydrolysis of the acyl group does not affect the absorption. The kcat and Km values were 
obtained by curve-fitting the Vinitial/[E] versus [S] plot using KaleidaGraph. For Sirt5 R105M, the 
observed second order rate constant, kobs (rate/([Sirtuin][NAD])) was detected instead of kcat and 
Km because of the very weak deacylation activity. The experiments were done in duplicate.    
For comparing the deacetylation, demalonylation and desuccinylation activities of Sirt5 on 
different peptide backbones (results shown in Table 6.3), histone H3, GDH and ACS2 peptides 
with two tryptophan residues at the C-terminal were used to allow better detection and 
quantification on HPLC. The peptide sequences were listed in Table 6.4. The determination of kcat 
and Km was carried out essentially the same as mentioned above with slight modifications. The 
reactions were quenched with 60 L 10% TFA. The chromatography gradient was 0% to 50% B 
for 20 min (1 mL/min). The peptides were detected and quantified on the LC by the absorption at 
280 nm. 
Detection of succinyl lysine from bovine liver mitochondrial proteins using the 32P-NAD 
assay. 
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Bovine liver mitochondria was isolated as previously described. Mitochondria from 5 g bovine 
liver was lysed for 30 min at 4°C in ice-cold lysis buffer (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 
0.1% Triton X-100) containing protease cocktail inhibitor (P8340, Sigma). The supernatants were 
collected and exchanged to 25 mM Tris-HCl (pH 8.0) with 50 mM NaCl using centrifugal filter 
(MILLIPORE, Billerica, MA) to remove endogenous NAD.  The extracts were stored at -80°C.  
For trypsin digestion, 1.5 mg of the bovine liver mitochondria proteins or BSA (used as the 
control) was dissolved in 6 M urea, 60 mM Tris-HCl (pH 8.0), 15 mM DTT in a reaction volume 
of 450 L. The solution was heated at 95°C for 15 min and then cooled to room temperature. 
Then 22.5 L of 1M iodoacetamide (final concentration ~50 mM) was added and the mixture was 
incubated at room temperature with gentle mixing for 1 h. Then 3.6 mL of 50 mM Tris-HCl (pH 
7.4) with 1 mM CaCl2 was added to the reaction mixture to lower the urea concentration to 0.75 
M.  Finally, 150 L of 100 g/mL modified trypsin (Promega Corporation, Madison, WI) were 
added and the reaction mixture was incubated at 37 °C for 12 h. After quenching the reaction by 
adding 65 L 10% TFA to pH 2~3, the digested peptides were desalted by using Sep-Pak C18 
cartridge 1cc/50 mg (Waters Corporation, Milford, MA) and lyophilized.  
To detect the acyl-ADPR compounds formed in sirtuin-catalyzed deacylation reactions, reactions 
were performed in 10 L solutions with 1 Ci 32P-NAD (ARC Inc., ARP 0141, 800Ci/mmol, 
0.125M), 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM DTT. The acyl peptide substrates 
used were 100 M H3K9 acetyl, malonyl, or succinyl peptide, 2 g calf thymus histones (Roche 
Applied Science, Indianapolis, IN), 20 g bovine liver mitochondrial peptides, or 20 g BSA 
peptides. The reactions were incubated with 1 M Sirt5 or Sirt1 at 37°C for 1 h. CD38 catalytic 
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domain was used to generate ADPR as a control. A total of 0.5 L of each reaction were spotted 
onto silica gel TLC plates and developed with 7:3 ethanol:ammonium bicarbonate (1 M aqueous 
solution). After development, the plates were air-dried and exposed to a PhosphorImaging screen 
(GE Healthcare, Piscataway, NJ). The signal was detected using a STORM860 phosphorimager 
(GE Healthcare, Piscataway, NJ). 
Detection of lysine succinylation on CPS1 peptides using the 32P-NAD assay 
The CPS1 band was cut from a SDS-PAGE gel of the bovine liver mitochondria lysate. The 
protein was in-gel digested with trypsin and extracted and desalted as the following. The gel band 
was washed in 100 L water for 5 min, followed by 100 L 100 mM Ammonium bicarbonate : 
acetonitrile (1:1) for 10 min and finally 50 L acetonitrile for 5 min. The acetonitrile was then 
discarded and the gel band was allowed to dry in the ventilated fume hood for 5-10 min. The gel 
slice was then rehydrated with 15 L trypsin solution (10 g/mL modified trypsin in 1mM HCl) 
on ice for 30 min. The trypsin solution was topped with 10 L 50 mM Ammonium bicarbonate 
with 10% acetonitrile. The digestion reactions were kept at 30°C for 12 h. The resulting solution 
was acidified with formic acid (1% in final). The trypsin digested peptides were extracted twice 
with 30 μl of 50% acetonitrile with 0.2% TFA (45 min incubation at room temperature followed 
by 5 min sonication). The third extraction was done with 30 μl of 90% acetonitrile with 0.2% 
TFA (5 min). All the extracts were combined and lyophilized. When dried, the peptides were 
dissolved in 12 μl of 0.1% TFA and desalted by ZipTips (Millipore, Bedford, Massachusetts).  
The desalted peptides were lyophilized again and reconstituted in water. The GDH peptides from 
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in-gel digestion and the histone peptides from in-solution digestion were prepared as described 
above. The 32P-NAD assays were carried out as described above. To lower the detection limit, 
higher concentrations of sirtuins were used. The Sirt5 was used at a final concentration of 52 M 
and the Hst2 was used at 24 M. The sample peptides were used at a concentration of 0.3 μg/μl 
and the control peptides were at 20 μM. 
Generation of Sirt5 deficient mouse line 
Sirt5 +/+ and -/- mice were generated at the Institut Clinique de la Souris (Strasbourg, France). 
Briefly, exon 4 of Sirt5 locus was flanked with loxP sites using standard genetic engineering and 
gene targeting procedures. The resulting Sirt5 floxed mice were bred with CMV-Cre transgenic 
mice to generate germline Sirt5 deficient (Sirt5 -/-) mice and control Sirt5 +/+ mice. The absence 
of Sirt5 mRNA in different tissues of Sirt5 -/- mice was confirmed by Q-RT-PCR analysis and 
the loss of Sirt5 protein expression was verified by western blot using an anti-Sirt5 antibody 
(Abcam ab62740) 
Preparation of liver lysate from Sirt5 wt and KO mouse 
The 29-week-old male Sirt5 +/+ and -/- littermates were fasted overnight (from 6:00 PM to 10:00 
AM) and then provided with free access to food for four hours prior to sacrifice. Liver tissues 
were rapidly removed, snap-frozen with liquid nitrogen, and stored at -80°C for analysis. The 
liver samples were first broken into small pieces, and then homogenized in 1mL of the lysis 
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% NP-40, 10% glycerol).  
The crude lysates were incubated at 4°C on shaker for 30 min then centrifuged at 10 000 g, 4°C 
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for 10 min. The concentration of the lysate was determined by Bradford assay.   
CPS1 activity assay 
CPS1 activities assay was carried out as described by Fahien and Cohen(23). The reaction was 
initiated by addition of the liver lysates to the rest of the reaction mixture. The reaction mixture 
contained 50mM Tris-HCl pH 8.0, 2.5 mM phosphoenopyruvate, 0.2 mM NADH, 30 mM NH4Cl, 
100 mM KHCO3, 5 mM ATP, 10 mM MgSO4, 10 mM  N-acetylglutamate, 15 U/ml pyruvate 
kinase / lactate dehydrogenase (SIGMA P0294). The reactions were performed at 37 degree and 
the decrease in absorbance at 340 nm was monitored. The initial velocity of the reaction was 
calculated to get the CPS1 activity. The activity assay was done with three pairs of Sirt5 wt and 
KO mice. 
Digestion of selected proteins for nano LC-MS/MS analysis 
Commercial GDH (Sigma G2626), malate dehydrogenase (Sigma M2634), citrate synthase 
(Sigma C3260), and pyruvate dehydrogenase (Sigma P7032) were in-solution digested with 
trypsin.  Typically, 1.0 mg of the protein was dissolved in 6 M guanidine hydrochloride, 150 
mM Tris-HCl (pH 8.0), 15 mM DTT in a reaction volume of 400 L. The solution was incubated 
at room temperature for 60 min. Then 20 L of 1M iodoacetamide (final concentration ~50 mM) 
was added and the mixture was incubated at room temperature with gentle mixing for another 60 
min. The excess iodoacetamide was quenched with 40mM DTT.  Then 3.6 mL of 50 mM Tris-
HCl (pH 7.4) with 1 mM CaCl2 was added to the reaction mixture to lower the guanidine 
hydrochloride concentration to 0.6 M.  Finally, 100 L of 100 g/mL modified trypsin (Promega 
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Corporation, Madison, WI) were added and the reaction mixture was incubated at 37 °C for 12 h. 
After quenching the reaction by adding 65 L 10% TFA to pH 2~3, the digested peptides were 
desalted by using Sep-Pak C18 cartridge 1cc/50 mg (Waters Corporation, Milford, MA) and 
lyophilized prior to nanoLC-MS/MS analysis. 
Identification of protein acylation by nanoLC-MS/MS analyses.  
The tryptic digest was reconstituted in 50 L of 2% acetonitrile with 0.5% formic acid and about 
200 ng of tryptic digest were injected for nanoLC-ESI-MS/MS analysis. The initial analysis was 
performed in UltiMatePlus nanoLC (Dionex, Sunnyvale, CA) coupled with to a hybrid triple 
quadrupole linear ion trap mass spectrometer, 4000 Q Trap from ABI/MDS Sciex (Framingham, 
MA) equipped with Micro Ion Spray Head II ion source. Most of final analyses were carried out 
using UltiMate3000 nanoLC (Dionex, Sunnyvale, CA) coupled with a LTQ Orbitrap Velos 
(Thermo-Fisher Scientific, San Jose, CA) mass spectrometer equipped with “Plug and Play” nano 
ion source device (CorSolutions LLC, Ithaca, NY). 
Tryptic peptides were separated on a PepMap C-18 RP nano column (5 µm, 75 µm i.d.  150 mm, 
Dionex), eluted in a 60 to 90-minute gradient of 10% to 40% acetonitrile in 0.1% formic acid at 
300 nL/min. For 4000 Q Trap analysis, MS data acquisition was acquired using Analyst 1.4.2 
software (AB SCIEX, Framingham, MA) in the positive ion mode for information dependent 
acquisition (IDA) analysis with nanospray voltage at 1.85 kV and heated interface at 150°C used 
for all experiments. In IDA analysis, after each survey and an enhanced resolution scan, three 
highest intensity ions with multiple charge states were selected for tandem MS (MS/MS) with 
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rolling collision energy applied for detected ions based on different charge states and m/z values. 
For Orbitrap analysis, each of tryptic digests was first acquired at CID-based parallel data-
dependent acquisition (DDA) mode where FT mass analyzer was used for an MS survey scan 
followed by MS/MS scans on top 7 most intensity peaks with multiple charged ions above a 
threshold ion count of 5000 in LTQ mass analyzer. A time-based target acylated peptide inclusion 
list was then generated based on the preliminary results from CID mode. Finally HCD-based 
DDA mode with inclusion list was applied for confirmation of acylation modification, where one 
FT survey scan was followed by 5 MS/MS scan in FT analyzer. MS survey scans and MS/MS 
scans were acquired at a resolution of 60,000 and 7,500 (fwhm at m/z 400) respectively.  The 
nano ion source was operated in positive ion mode with a voltage set at 1.5 kV and ion transfer 
tubing temperature at 225 °C. Either internal calibration using a background ion signal at m/z 
445.120025 as a lock mass or external calibration using Ultramark 1621 for FT mass analyzer 
was performed. The normalized collision energy for CID and HCD were set at 35 % and 38% 
respectively. All data were acquired under Xcalibur 2.1 operation software (Thermo-Fisher 
Scientific).  
Data analysis.  
The MS/MS data generated from both 4000 Q Trap and LTQ Orbitrap Velos were submitted to 
Mascot 2.3 (Matrix Science, Boston, MA) for database searching using in-house licensed Mascot 
local server and the search was performed to query to SwissProt database (taxonomy: mammal) 
with three missed cleavage sites by trypsin allowed.  The peptide tolerance was set to 1.2 Da and 
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MS/MS tolerance was set to 0.6 Da for the data from 4000 Q Trap. For Orbitrap data, the peptide 
tolerance was set to 10 ppm and MS/MS tolerance was set to 0.6 Da (for MS/MS spectra acquired 
by LTQ) and 0.05 Da (MS/MS spectra acquired by Orbitrap FT mass analyzer). A fixed 
carbamidomethyl modification of cysteine and several variable modifications on lysine 
acetylation, malonylation, succinylation, and carbamylation, deamidation of asparagine and 
glutamine, and methionine oxidation were applied. Only significant scores for the peptides 
defined by Mascot probability analysis (www.matrixscience.com/help/scoring_help.html#PBM) 
greater than “identity” were considered for the peptide identification and modification site 
determinations. All MS/MS spectra for the identified peptides with acylation modifications were 
manually inspected and validated using both Proteome Discoverer 1.2 and Xcalibur 2.1 software 
(Thermo-Fisher Scientific, San Jose, CA).   
Relative quantitation of acylated peptides by nanoLC-MS/MS analysis   
For relatively quantitative analysis of acylated peptides across samples, the peak areas of detected 
precursor ions at each specific m/z corresponding to the acylated peptides were determined by 
extracted ion chromatogram (XIC). The XIC of two independent (non-target), tryptic peptides 
identified from the same proteins in the same LC-MS/MS runs were also used as reference 
control for normalization of loaded sample digests. Specifically, we acquired nanoLC-MS/MS 
files in triplicate by Orbitrap at HCD mode as described above for identification of acylated 
peptides. The peak area of target acylated peptides in one LC-MS/MS data file was first extracted 
using Xcalibur 2.1 software with mass tolerance at 5ppm and mass precision at 4 decimal. A 
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layout template file was then generated and applied to all LC-MS/MS data files yielding peak 
area of all peptides of interest. Finally, peak area of each acylated peptide in each protein was 
normalized to the peak areas of the two reference peptides in each LC/MS/MS data file. The 
relative standard deviation (RSD) for most acylated peptides in three XIC measurements is less 
than 20%. 
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